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Abstract 
The years following treatment are often associated with physical and mental health 
sequelae for cancer survivors and caregivers. They may be more distressing for survivors and 
caregivers of leukemia and lymphoma than solid tumor survivors. Survivors of life-threatening 
illnesses have been found to show positive biopsychosocial changes, termed posttraumatic 
growth. Cancer survivors with more severe diagnoses often display higher levels of 
posttraumatic growth. Positive and negative biopsychosocial changes may be more pronounced 
among caregivers and survivors of leukemia and lymphoma than of solid tumors. This is the first 
study to compare biopsychosocial changes following cancer diagnoses among solid versus non-
solid cancer survivors and caregivers. 
Fifty-one cancer survivors and their caregivers were recruited online through classified 
advertisements for research participants and snowball sampling. They completed a demographic 
questionnaire including questions about their diagnoses, treatments, and perceived cancer 
severity along with a battery of questionnaires measuring different domains of adjustment to 
cancer including: posttraumatic growth, negative biopsychosocial changes due to cancer, health-
related quality of life, and social support. Chronbach Alphas were conducted to demonstrate the 
internal consistency for questionnaire data among the caregiver and survivor subgroups of the 
sample. Correlation matrices were calculated for questionnaire data among caregivers and 
survivors to demonstrate the relationships between the different outcome variables. Multiple 
regressions and t-tests were conducted to test the differences in levels of posttraumatic growth, 
negative biopsychosocial changes attributed to cancer, health-related quality of life, and social 
support among solid versus non-solid tumor survivors and caregivers. 
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The results from the hypothesis testing did not suggest that a diagnosis of a solid versus 
non-solid tumor nor a higher degree of perceived severity of diagnosis predicted significant 
differences in posttraumatic growth, negative biopsychosocial changes related to cancer, health-
related quality of life, or social support. This is likely partially due to the small sample size 
utilized in this study and the impact of potential moderators including: social economic status, 
comorbid medical conditions, and time since treatment cessation. Further research into 
biopsyhosocial adjustment to cancer survivorship and care giving could facilitate understanding 
and provision of services to address the biopsychosocial needs of cancer survivors and caregivers.  
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Chapter 1. Introduction 
Leukemia and lymphoma are classified as non-solid tumors that occur in the 
hematopoietic stem cells, found in bone marrow, and lymphatic cells, respectively (Jaffe, Harris, 
Stein, & Vardiman, 2001). The National Cancer Institute estimated the prevalence of leukemia 
and lymphoma in the United States to be 1,735,350 and the incidence to be 174,250 each year 
based on data regarding the trends in incidence rates over recent years (Leukemia and 
Lymphoma Society, 2018). For the purpose of this dissertation, individuals in treatment for 
cancers, such as leukemia and lymphoma, will be referred to as patients and those who have 
completed treatment will be referred to as survivors. 
Common Diagnoses 
There are over 50 identified subtypes of leukemia and lymphoma (see Appendix A for a 
complete list). In the United States, the most common diagnoses within the categories of 
leukemia and lymphoma are non-Hodgkin lymphoma, followed by acute myeloid leukemia, 
chronic lymphocytic leukemia, Hodgkin lymphoma, acute lymphoblastic leukemia, and chronic 
myeloid leukemia (Leukemia and Lymphoma Society, 2014). Non-Hodgkin lymphoma is the 
most common class of diagnoses of non-solid tumors and describes a number of B-cell 
malignancies, which are disordered development of a subclass of white blood cells in the 
immune system that travel through the lymphoid tissue (Evans & Hancock, 2003). In contrast, 
Hodgkin lymphoma is characterized by a mutation of lymphatic cells into Reed-Sternberg cells, 
large cells that typically have more than one nuclei, often associated with the Epstein-Barr virus 
(Küppers and Rajewsky, 1998). Hodgkin lymphoma can cause lymphocyte depletion, which 
reduces the effectiveness of the immune system. 
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Acute Myeloid Leukemia (AML) refers to a sudden proliferation of immature blood cells 
in the bone marrow due to a mutation (Shipley & Butera, 2009). Chronic Myeloid Leukemia 
(CML) also refers to a mutation in the stem cells that develop into blood cells in the bone 
marrow, leading to an increase in immature blood cells but is associated with a slower onset 
(Hehlmann, Hochhaus, & Baccarani, 2007). Chronic lymphocytic leukemia (CLL) arises due to a 
mutation in the bone marrow leading to impaired B-cell receptor activity and low production of 
blood cells, resulting in anemia (Dighiero & Hamblin, 2008). Acute lymphoblastic leukemia 
(ALL) involves a proliferation in immature blood cells that often block the development of 
functioning mature cells and typically peaks in early childhood but can affect adults as well 
(Inaba, Greaves, & Mullighan, 2013). 
Staging 
Staging refers to the process in which the clinical severity of a cancer, including such 
factors as the size of a tumor and the degree to which it has spread outside of the original 
location, is determined through medical assessment, such as biopsy and blood tests (National 
Cancer Institute, 2018). In cases of non-solid tumors, the categories in which the cancer is staged, 
the criteria by which the tumors are classified, and the prognostic value provided by the stages 
vary substantially by diagnostic subtype (e.g. American Cancer Society, 2018; National Cancer 
Institute, 2018). Understanding of the severity, risk for recurrence, and risk of death from cancer 
and its treatment often is significantly different between cancer patients/survivors and their 
medical providers and this difference is particularly pronounced among patients/survivors of 
non-solid tumors (e.g. El-Jawahri et al., 2017; Shimer et al., 2018). Difficulties in 
communications between patients and medical providers, as well as the overall complexity of the 
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staging processes and the results of these processes may contribute to misunderstandings among 
patients/survivors about the severity of their diagnoses. 
Treatment 
Like many other types of cancers, leukemia and lymphoma are typically treated with 
chemotherapy, radiation therapy, biological therapy, and/or bone-marrow transplantation, 
depending on the diagnosis, stage, and patient characteristics (e.g. general health). Chemotherapy 
describes medications administered intravenously, directly into the central nervous system fluid, 
or orally that are formulated to destroy malignant cells (Leonard, 1998). For certain cancers, 
such as Hodgkin lymphoma, the chemical formulation is able to specifically target the specific 
genetic makeup of the cancer cells. However, the effectiveness of chemotherapy is more 
effective for certain types of cancers, such as Hodgkin lymphoma, than for others, such as many 
forms of non-Hodgkin lymphoma. The degree to which the cancer has progressed also impacts 
the efficacy of chemotherapy. Chemotherapy can also be toxic to other cells as well, causing 
different side effects including nausea, intense fatigue, hair loss, changes in smell and taste, 
neuropathy, anemia, and increased susceptibility to infection (Cherrier-De Wilde, 2013). In 
certain patients, these side effects can be lethal. Careful monitoring and dosage adjustments are 
necessary to ensure that these concerns do not outweigh their benefits.  
Radiation therapy involves directing a concentrated dose of radiation to the site of a 
particular tumor (Leonard, 1998). This burns cancer cells, thereby killing them. Although 
radiation therapy can kill cancer cells, it can also cause mutation in nearby healthy cells that can 
develop into different tumors, known as secondary malignancies (Travis, Allan, Pui et al., 2011). 
Radiation therapy can also damage nearby cells, causing a range of problems depending on the 
location, including cardiovascular disease, which can be fatal. 
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Treatments that utilize large quantities of substances produced by the human body to 
counteract malignant cells are known as biological therapies (Leonard, 1998). These include the 
drug interferon, commonly used to treat leukemia. Interferon is a cytokine; they assist the body’s 
immune response to cancer cells, disrupt cancer cell growth, and assist in the development of 
normal cells. Side effects and complications of biological treatment vary depending on the type 
of treatment and dosage and include fatigue, insomnia, depression, thrombocytopenia, anemia, 
and congestive heart failure (Foon, 2012). 
In certain cases, bone marrow can be harvested from donors or the cancer patient while in 
remission and transplanted into the cancer patient while the disease is active (Leonard, 1998). 
This is a fairly common treatment in leukemia patients and involves destroying the patient’s 
current bone marrow using high doses of chemotherapy and/or radiation therapy. When the 
transplanted bone marrow comes from a source other than the patient, there is a risk of a 
condition called graft-versus host disease in which the T-cells in the donor bone marrow attack 
tissue or organs in the bone marrow recipient (Blazar, Murphy, & Abedi, 2012). This condition 
can be fatal if it is resistant to treatment with immunosuppressant drugs.  
Evidence based treatment for non-Hodgkin lymphoma varies depending on the exact type 
of lymphoma but generally includes some form of chemotherapy and radiation therapy (Evans & 
Hancock, 2003). AML is typically treated with chemotherapy, and/or stem cell transplantation 
once the patients are in remission, depending on their general health (Shipley & Butera, 2009). 
Following remission, treatment with an additional regiment of chemotherapy and/or bone 
marrow transplantation may be implemented to improve survival and cure rates. CML is highly 
responsive to treatment with a small-molecule pill that when taken daily, suppresses the cell 
proliferation of the cancer cells (Hehlmann et al., 2007). Chemotherapy, radiation therapy, and 
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hormone therapy are often utilized with intermediate and advance staged CLL patients; however, 
they carry a variety of risks including infection, secondary malignancies, and hematological 
toxicity (Halleck et al., 2008). In many early-stage CLL cases, the risk of treatment due to side 
effects and complications often outweighs foreseeable benefits and watchful waiting is the best 
practice treatment unless the disease progresses. Hodgkin lymphoma often responds well to 
treatment with chemotherapy and radiotherapy (Girinsky et al., 2006). ALL is typically treated 
with up to 4 years of chemotherapy (Inaba et al., 2013). 
Prognosis 
The prognosis of non-Hodgkin lymphoma varies widely depending on the size and 
location of the tumor(s), the stage, and the general health of the patient (Evans and Hancock, 
2003). The particular genetic abnormality associated with the cancer cells is the best predictor of 
prognosis (Grimwade et al., 1998). Hodgkin lymphoma is often curable with chemotherapy and 
radiation therapy, however complications and secondary malignancies can occur when radiation 
therapy is not implemented optimally (Girinsky et al., 2006). 
Without treatment, AML is fatal within several weeks to months (Shipley & Butera, 2009). 
Even with best practice treatment, AML patients often do not survive for more than two years 
after treatment. With evidence-based treatment, CML has a good prognosis for most patients 
(Hehlmann et al., 2007). The course and prognosis of CLL varies widely, with patients surviving 
from several months to multiple decades after diagnosis (Dighiero & Hamblin, 2008). Staging is 
not always an optimal predictor of prognosis. When diagnosed in early childhood, the prognosis 
for ALL is optimistic; however, ALL does not respond as well to treatment in adulthood (Inaba 
et al., 2013). In general, the five-year survival rate estimates are up to 88% for Hodgkin 
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lymphoma, 79% for non-Hodgkin lymphoma, and 59% for leukemia (Siegel, Ma, Zou, & Jemal, 
2014).  
As such, the majority of leukemia and lymphoma survivors (LLS) are living well past 
their original diagnosis. These LLS need to re-adjust to their daily lives with new strengths and 
limitations following treatment and, in the case of chronic lymphocytic leukemia and chronic 
myeloid leukemia, over the course of ongoing treatment (Parry, Morningstar, Kendall, & 
Coleman, 2011).  
Cost of Treatment 
 The out-of-pocket costs for treatment in the United States is high even with insurance. 
The National Cancer Institute (2010) estimated that prior to the Affordable Care Act, the average 
costs for the first year of treatment when patients were insured were as follows: $33, 167 for 
female leukemia patients, $57, 881 for female lymphoma patients, $36, 036 for male leukemia 
patients, and $60, 701 for male lymphoma patients. This can often mean substantial debt for LLS 
and their families (Parry et al., 2011). The Affordable Care Act has set a maximum per policy 
period for out-of-pocket health care expenses at $6,600 for individuals and $13 200 for families, 
affecting all enrollees (HealthCare.gov, 2014). It is hoped that this will have a significant impact 
on the financial situation of LLS.  
Health Related Quality of Life in Leukemia and Lymphoma Patients 
 Health related quality of life (QOL) measures an individual’s functioning across a variety 
of domains related to disease and disorder, including issues related to finances (Guyatt, Feeny, & 
Patrick, 1993). Understanding health related QOL is important in determining the impact a 
disease, disorder, or treatment has on the overall wellbeing of patients and survivors.  
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While actively in treatment for their cancers, leukemia and lymphoma patients face a 
variety of concerns related to their QOL. A study from Sweden showed a marked deterioration in 
multiple areas of QOL over the course of treatment for patients with acute leukemia or advance 
stage lymphoma (Persson, Larsson, Ohlsson, & Hallberg, 2001). The highest levels of 
deterioration were in ability to function across the social domain and the various roles required 
for independent living, such as employment and household duties. Health related QOL was 
inversely related to psychological distress in leukemia and lymphoma patients in the United 
Kingdom (Montgomery, Pocock, Titley, & Lloyd, 2002). Concerns about receiving inadequate 
information on their diagnoses and treatment options were common. 
While most studies on health related QOL have focused on the effects of cancer 
treatments, there is some evidence to indicate that the cancers themselves contribute to changes 
in functioning. The level of circulating cytokines was associated with various measures of 
cognitive impairment, fatigue, and overall QOL in a study on patients with AML and 
myelodysplastic syndrome in the United States (Meyers, Albitar, & Estey, 2005). 
Negative Biopsychosocial Changes Following a Cancer Diagnosis/Treatment 
Multi-disciplinary health care providers and researchers have become increasingly aware 
of the psychosocial distress cancer survivors suffer from following treatment (e.g. Parry et al., 
2011). This is typically conceptualized as decreases in health related QOL following the 
cessation of cancer treatment (e.g. Holland and Rexnik, 2005; Bishop et al., 2007). Information 
on specific psychosocial challenges faced by LLS survivors is limited; however, there is a 
growing body of evidence on such challenges across a variety of groups of cancer survivors (e.g. 
Connerty & Knott, 2013; Stanton et al., 2005), much of which might be relevant to LLS. In 2008, 
the Institute on Medicine published a report urging cancer care providers to arrange for cancer 
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survivors to receive assistance in a variety of psychosocial domains following treatment 
cessation. These recommendations include adequate provision of information about diagnoses 
and available services, financial assistance, and support for associated distress. 
The months and years following treatment can often be more psychologically challenging 
for cancer survivors than diagnosis and treatment (Holland and Rexnik, 2005). While actively in 
treatment, many cancer patients do not have the time or energy to adequately process their 
experience with cancer (Stanton et al., 2005). This processing typically happens following 
treatment. Studies on cancer survivorship have found that survivors often are preoccupied with 
anxiety and hypervigilance about potential signs of cancer recurrence (e.g. frequently checking 
for swollen lymph nodes), feel abandoned by their health care providers when visits become less 
frequent, and do not think that the health care system adequately addressed their needs (e.g. 
Deimling, Kahana, Bowman, & Schaefer, 2002; Parry et al., 2011). Fear of recurrence was 
correlated with additional health problems and family stressors among cancer survivors in the 
United States (Mellon, Kershaw, Northouse, & Freeman-Gibb, 2007). Cancer survivors have 
also reported that their loved ones often do not understand the extent to which cancer has 
changed their lives (Connerty & Knott, 2013). 
Survivorship Challenges among Caregivers of Cancer Survivors  
 Caregivers of cancer survivors often face similar challenges once their loved ones 
complete treatment. One domain in which such difficulties emerge is health related QOL. Bishop 
and colleagues (2007) conducted a study on American cancer survivors who had received 
hematopoietic stem-cell transplantation, their spouses, and healthy controls. They found that the 
spouses of survivors endorsed sleep difficulties, sexual problems, and depressive symptoms at 
rates greater than among healthy controls.  
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 Fear of recurrence is a common concern among both cancer survivors and their loved 
ones. Mellon and colleagues (2007) found that families of cancer survivors in the United States 
endorsed a greater level of fear of recurrence than the survivors themselves. Correlates of fear of 
recurrence among family members of cancer survivors included additional family stressors and 
the meaning that caregivers attached to the cancer in relation to the family’s identity and 
functioning. In an American study on cancer-related distress in cancer survivors and their 
caregivers, Matthews (2003) found that caregivers endorsed higher levels of overall distress and 
fear of recurrence than the cancer survivors.  
 There is some evidence that diagnoses and demographic variables impact caregiver 
challenges in different ways. Kim, Wellisch, Spillers, and Crammer (2007) found that American 
female caregivers of breast cancer and ovarian cancer survivors reported lower levels of distress 
than survivors of cancer types experienced by both sexes, such as lung cancer, leukemia, and 
lymphoma. Age was inversely related to the level of unmet psychosocial, medical, and financial 
needs endorsed by American cancer caregivers (Kim, Kashy, Spillers, & Evans, 2010). At two 
years following the diagnosis, female caregivers reported greater unmet psychosocial needs than 
their male counterparts. Greater unmet needs were associated with more mental health concerns 
for survivors (Kim et al., 2010). Kim and colleagues (2008) found that the level of dissimilarity 
in distress experienced between prostate cancer survivors and their wives predicted increased 
mental health concerns for the spouses. Dissimilarity in distress levels conversely predicted 
better physical health in husbands of breast cancer survivors. 
LLS-Specific Biopsychosocial Changes Following Diagnosis/Treatment 
Lingering physical effects, such as fatigue and neuropathy, are also often a concern for 
LLS in the months and years following treatment cessation (Parry et al., 2011; Jones, Parry, 
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Devine, Main, & Okuyama, 2015). The large variability amongst diagnoses, prognoses, and age 
of onset in LLS can often lead to fewer commonalities in the biological and psychosocial 
impacts of cancer in individuals with LLS as compared to those of more common and/or 
heterogeneous cancers (Jones et al., 2015). This can cause feelings of isolation for survivors 
whom often have difficulty finding support from fellow survivors whom experience the same 
types of psychosocial concerns following treatment.  These factors also may lead to difficulties 
finding information that fully addresses survivors’ concerns in a manner that is easy to 
comprehend and readily available (Parry et al., 2011). The financial burden of treatment is also a 
concern amongst many cancer survivors in the United States and particularly when there are 
limited sources of financial support for the particular diagnoses, such as leukemia and lymphoma. 
The costs of after care, such as follow-up visits, scans, and blood tests, are often cost-prohibitive 
to survivors already financially strained and can lead to insufficient monitoring for recurrence 
(Parry et al., 2011). In addition, many LLS find that they cannot continue to satisfy occupational 
requirements due to the physical sequelae of their cancer and treatment, further limiting their 
financial resources following treatment.  
Course of Negative Biopsychosocial Changes among LLS 
These concerns can last for years following the cessation of cancer treatment. Syrjala and 
colleagues (2003) followed a cohort of LLS who had received hematopoietic stem cell 
transplantation in the United States for five years post-treatment. By the five-year follow-up 
assessment, only 63% of participants who had not experienced recurrence were functioning 
without major physical, psychological, or occupational concerns. Poorer psychological 
functioning at five years post-treatment was associated with a higher risk for recurrence and/or 
complications following treatment (Syrjala et al., 2004). At a 10-year follow-up assessment of 
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quality life among LLS in the United States, Lim and Zebrack (2006) found that QOL was 
related to the size and strength of survivors’ social networks. This relationship was mediated via 
use of supportive services (e.g. support groups and psychotherapy).  
While much of the work on health related QOL in patients with leukemia and lymphoma 
focuses on the side effects of treatment, there is some evidence that the cancers might impact 
QOL independently of the treatments. A study from the United States investigated the levels of 
QOL, fatigue, cognitive impairment, and cytokine levels in patients prior to treatment for AML 
or myelodysplastic syndrome (Meyers, et al., 2005). Although overall QOL did not appear to be 
impaired prior to treatment initiation, significant cognitive impairment and fatigue were found. 
Correlates of Negative Biopsychosocial Changes Following a Leukemia or Lymphoma 
Diagnosis 
Specific treatments might also play a role in influencing survivorship concerns among 
LLS. A study from the Netherlands investigated the health related QOL among non-Hodgkin 
lymphoma survivors 5-15 years following diagnosis (Mols et al., 2007). Survivors who received 
chemotherapy were found to experience more health related QOL problems than survivors who 
received watchful waiting or radiation therapy alone. Financial concerns were prominent among 
this group, including difficulty obtaining a home mortgage and fulfilling job responsibilities due 
to their cancer diagnosis and treatment (Mols et al., 2007). A study from Norway examined 
changes in QOL following stem cell transplantation from a donor and chemotherapy compared 
to those who received stem cell transplantation from their own tissue one to three years 
following treatment (Hjermstad et al., 2004). They found improvements in health related QOL 
among all groups with greater improvements found among the group receiving stem cell 
transplantation from a donor and chemotherapy.  
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Posttraumatic Growth 
 Posttraumatic growth refers to positive biopsychosocial changes that occur to individuals 
following the experience of traumatic events (Tedeschi & Calhoun, 1995). These changes vary 
from individual to individual in patterns that are similar among survivors of similar crises (Park, 
2004). Positive changes following traumatic events allow individuals to not only survive their 
stressful situation, but to rise above it to a greater level of personal development than they were 
at prior to their crisis (Zoellner & Maercker, 2006). This growth often occurs through changes in 
self-perception, such as recognizing one’s own strength in overcoming a crisis, outlook on life, 
social support, and spirituality (Tedeschi & Calhoun, 1995). There is some evidence suggesting a 
positive correlation between experiencing posttraumatic growth and adjusting to new life 
circumstances as a result of the trauma (Zoellner & Maercker, 2006). It has also been proposed 
that posttraumatic growth can serve as a form of avoidance of the negative emotions associated 
with trauma (Zoellner & Maercker, 2006).  
Posttraumatic growth has been found in a variety of populations of trauma survivors 
including refugees displaced due to combat (Powell, Rosner, Butollo, Tedeschi, & Calhoun, 
2003), survivors of natural disasters (Cryder, Kilmer, Tedeschi, & Calhoun, 2006), and survivors 
of terrorist attacks (Laufer & Solomon, 2006). Although the specific patterns of posttraumatic 
growth appear to differ among these heterogeneous groups of trauma survivors, common themes 
appear across groups (e.g. Park, 2004; Zoellner & Maercker, 2006). Schema changes to 
accommodate the experience of surviving the trauma have been proposed as a potential 
explanation for posttraumatic growth (Janoff-Bulman, 2004). Research suggests that there 
appears to be a positive relationship between the severity of the trauma experienced and the 
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degree of growth, with participants who experienced a greater severity of trauma showing more 
posttraumatic growth (e.g. Tedeschi & Calhoun, 1995; Tedeschi & Calhoun, 2004). 
Posttraumatic Growth in Cancer Patients and Survivors 
 Posttraumatic growth has been found in a number of groups of cancer survivors. It has 
been investigated in survivors of breast cancer (Sears, Stanton, & Danoff-Burg, 2003; Cordova, 
Cunningham, Carlson, & Andrykowski, 2001; Bellizzi & Blank, 2006), cancer treated with 
bone-marrow transplantation (Widows, Jacobsen, Booth-Jones, & Fields, 2005), gynecological 
cancer (Simonelli, Fowler, Maxwell, & Andersen, 2008; Ponto, Ellington, Mellon, & Beck, 
2010), childhood cancer (Yi & Kim, 2014), and adolescent cancer (Barakat, Alderfer, & Kazak, 
2005). The majority of these studies measured posttraumatic growth using the Posttraumatic 
Growth Inventory (PTGI) by Tedeschi and Calhoun (1995). The PTGI conceptualizes 
posttraumatic growth as positive change in the following domains: relationships with others, new 
opportunities, spiritual growth, appreciation for life, and increased personal strength. 
Psychological Correlates of Posttraumatic Growth among Cancer Patients and Survivors 
In a qualitative interview study on posttraumatic growth among survivors of a variety of 
cancers in Australia, common themes included facing death and re-evaluating priorities, 
increased appreciation for life, increased spirituality, and improved communication with loved 
ones (Connerty & Knott, 2013). Posttraumatic growth was inversely correlated with 
posttraumatic stress among a cohort of long-term survivors of childhood cancer (Yi & Kim, 
2014). 
A number of psychological coping mechanisms have been found to correlate with 
posttraumatic growth among cancer survivors. A study by Cordova et al. (2001) on breast cancer 
survivors found that the level of posttraumatic growth was positively correlated with the time 
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since the diagnosis and the amount of time spent talking about breast cancer. It appears that 
growth emerged gradually and was facilitated by reflection and processing of experiences related 
to their diagnoses in these individuals. Another study on breast cancer survivors found that the 
emotional impact of the cancer and use of coping mechanisms (e.g. seeking support and 
positively reinterpreting the situation) were related to the level of posttraumatic growth endorsed 
(Bellizzi & Blank, 2006). Survivors who had received bone marrow transplantation showed 
greater posttraumatic growth when they recalled their experiences with treatment and their pre-
morbid functioning more negatively than their peers. A study using a sample of gynecological 
cancer survivors found that one proposed aspect of posttraumatic growth, finding meaning in life, 
was associated with lower levels of mental health concerns and physical health limitations 
(Simonelli et al., 2008). Ho, Chan, Yau, and Yeung (2011) showed that posttraumatic growth in 
Chinese breast cancer patients appeared to be related to using a stable, internal, and global 
attributions to explain positive events. As such, these participants indicated that their personal 
qualities (e.g. strength) were the cause of the positive events and that changes would be long 
lasting and impact multiple domains in their lives beyond the original event. 
There is some indication that personality differences among cancer survivors predict the 
level of posttraumatic growth experienced. Posttraumatic growth positively correlated with the 
tendency to express gratitude among breast cancer survivors in Italy (Ruini & Vescovelli, 2013). 
A set of studies on posttraumatic growth among cancer patients in Poland indicated that 
individuals displaying higher levels of basic trust, using Erikson’s (1950) definition, were more 
likely to experience positive growth (Trzebinski & Zieba, 2013). This effect appeared to have 
been mediated by the degree to which participants engaged in positive reinterpretations of their 
experience with cancer and negative coping styles (e.g. hopelessness/helplessness). 
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Structural equation modeling has helped indicate potential pathways between cancer 
related distress and posttraumatic growth. In a sample of adult cancer survivors under 55 years 
old, posttraumatic growth was demonstrated to moderate the link between unwanted/involuntary 
thoughts and adjustment (Park, Chmielewski, & Blank, 2010). That is, individuals experiencing 
high level of posttraumatic growth, unwanted/involuntary thoughts predicted better adjustment 
as compared to those without such unwanted/involuntary thoughts. In a study on adult cancer 
survivors in Australia, the perceived severity of their diagnoses were shown to be related to 
survivors’ level of distress and their level of social support (Morris & Shakespeare-Finch, 2011). 
The level of social support endorsed by survivors mediated the relationship between the 
perceived severity of the diagnosis and posttraumatic growth. Unwanted/involuntary thoughts 
versus purposeful positive thoughts moderated the relationships between the perceived severity 
of the diagnosis, distress, and posttraumatic growth. 
Morris and colleagues (2011) conducted a qualitative study on changes in personal 
identity of a cohort of breast cancer survivors involved in Amazon Heart Thunder, a unique 
motorcycle-based peer support network in Australia and the United States. In pre-intervention 
interviews, participants’ descriptions of the degree to which they identified with the term breast 
cancer survivor varied and participants focused on cancer-related distress. Following the first 
motorcycle ride, many of the participants discussed increases in personal strength, finding role 
models, revisiting life priorities, and some who had not previously identified with the term breast 
cancer survivor changed their self-identity (Morris et al., 2011). Affiliation with survivors of a 
similar diagnosis during this empowering activity appeared to facilitate posttraumatic growth 
among these individuals. 
Correlates of Posttraumatic Growth among Cancer Patients and Survivors 
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Demographic variables and health-related QOL have been shown to correlate with 
posttraumatic growth in multiple studies with cancer patients. Several indicators of 
socioeconomic status were positively correlated with posttraumatic growth in survivors of breast 
cancer (Cordova et al., 2001; Bellizzi & Blank, 2006). However, demographic variables and 
health-related distress did not predict posttraumatic growth in adult cancer survivors under the 
age of 55 (Park et al., 2010). Park and Blank (2012) investigated the demographic correlates of 
positive and negative changes following cancer care across various diagnoses. A younger age at 
onset, more medical co-morbidities, and lower income were associated with increased 
survivorship distress. Females and survivors with fewer co-morbidities reported more 
posttraumatic growth than their peers (Park & Blank, 2012). Smith, Williams, Zimmer, and 
Zimmerman (2010) found that posttraumatic growth mediated the relationship between general 
aspects of QOL (e.g. social/family wellbeing) and their antecedents (e.g. social support) in non-
Hodgkin lymphoma survivors. However, this study did not utilize a measure of QOL that 
specifically addressed cancer survivorship concerns.  
Higher severity of diagnoses also appears to positively impact the level of posttraumatic 
growth seen in cancer survivors. Barakat and colleagues (2005) found that the physician-rated 
severity of the cancer diagnosis and treatment were predictive of posttraumatic growth in 
adolescent cancer survivors and their parents. Higher levels of posttraumatic growth have also 
been found among individuals with recurrent ovarian cancer, a typically fatal form of 
gynecological cancer, than in breast cancer survivors (Ponto et al., 2010). A study on childhood 
cancer survivors at least five years following treatment showed that individuals who received 
high risk chemotherapy or radiation therapy showed higher levels of posttraumatic growth than 
those who did not receive chemotherapy or radiation therapy (Zebrack et al., 2012). Survivors 
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who developed secondary malignancies or recurrence also endorsed higher levels of 
posttraumatic growth than their peers. Later age of diagnosis and shorter time since diagnosis 
were also related to a higher level of posttraumatic growth than other groups of survivors 
(Zebrack et al., 2012). 
Increased Health Behaviors among Cancer Survivors 
Increases in specific health-promoting behaviors following cancer treatment have also 
been found. In a study of increased positive physical and psychosocial health behaviors 
following cancer treatment across diagnoses, Harper et al. (2007) found that changes were most 
frequent in re-evaluating life priorities and eating healthy. The least frequent changes involved 
increasing physical exercise. Connerty and Knott (2013) found an increased involvement in 
researching their diagnoses and treatments, engaging in exercise, and healthy eating among 
survivors of multiple types of cancer. Several participants also reported being involved with 
support and advocacy groups. Another study from Australia on endometrial cancer survivors 
showed that participants endorsed a higher level of positive changes than negative changes 3-5 
years post-treatment (Rowlands et al., 2013). Health awareness was the most commonly 
endorsed positive change. 
Posttraumatic Growth in Caregivers of Cancer Survivors 
 Little research on posttraumatic growth in the caregivers of cancer survivors has been 
conducted to date. The studies that have been completed have indicated that caregivers of cancer 
survivors and patients display some level of posttraumatic growth in response to their loved ones’ 
illness. Weiss (2004) found posttraumatic growth in the husbands of breast cancer survivors that 
corresponded with the posttraumatic growth of their wives and the strength of their marital 
relationship. Childhood cancer survivors have been shown to display higher levels of 
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posttraumatic growth than their siblings (Zebrack et al., 2012). A study on posttraumatic growth 
among caregivers of cancer patients across diagnoses in Italy found that caregivers who were 
male and in the younger age-range endorsed higher levels of physical activity and more vitality 
than their peers.  
Bekteshi and Kayser (2013) studied relationship changes between mothers with breast 
cancer and their daughters under the age of 18 in the United States. Emerging themes from their 
interviews included: heightened awareness of the impact cancer had on each other and increased 
efforts to lessen such impacts, increased empathy and authenticity towards each other, and 
greater mutual empowerment. Mothers often reported transient periods of disconnectedness in 
their relationships with their daughters that were eventually repaired through mutual support and 
empathy (Bekteshi & Kayser, 2013). Kim and colleagues (2007) found higher levels of 
spirituality among female caregivers of breast cancer and ovarian cancer than female caregivers 
of gender non-specific cancers in the United States. Spirituality was shown to decrease 
psychological distress in caregivers of gender non-specific cancer survivors. 
One study from Kyoto, Japan suggested that posttraumatic growth among bereaved 
caregivers is associated with their loved one going through a “good death,” a concept related to 
patients’ comfort, relationships with others, and psychological well-being (Hatano, Fujimoto, & 
Fukui, 2015). 
In summary, cancer survivorship and caregiving for cancer survivors is often 
accompanied by a variety of positive and negative biopsychosocial changes. Non-solid tumor 
diagnoses, classified as leukemia or lymphoma, are associated with a greater degree of disease 
heterogeneity and an increased likelihood of recurrence following successful treatment compared 
to many solid tumor diagnoses, such as breast cancer or thyroid cancer. Survivors of leukemia 
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and lymphoma often endorse different understandings of their prognoses and likelihood of 
recurrence than their providers, which may be partially due to limited publicly accessible 
information on specific subtype diagnoses of leukemia and lymphoma. Positive biopsychosocial 
changes following a trauma, such as a cancer diagnosis, is referred to as posttraumatic growth 
and has been found in several populations of cancer survivors and caregivers of cancer survivors. 
Greater degrees of posttraumatic growth have been found to be related to greater severity of the 
diagnoses, as rated by physicians.  
Current Study 
The current study investigates the relationship between negative biopsychosocial changes 
following cancer diagnoses, posttraumatic growth, the diagnosis of a solid versus non-solid 
tumor, and the perceived severity of diagnoses among cancer survivors and caregivers. The 
experiences of this group of survivors and their caregivers differ greatly from the experiences of 
other cancer survivors for a variety of reasons including different evidence-based treatment 
modalities and the heterogeneity of the courses and outcomes of each disease. This heterogeneity 
often has the effect of reducing access to opportunities for financial and social support that are 
available to survivors of more common and relatively homogenous cancers.  
Post-traumatic growth is expected to increase with the perceived severity of diagnosis 
and among caregivers and survivors of non-solid versus solid tumors. To date, no study to our 
knowledge has addressed the differences in degrees of posttraumatic growth experienced 
between caregivers and survivors of non-solid versus solid tumors. Few studies have directly 
addressed the relationship between posttraumatic growth and negative biopsychosocial changes 
specific to the unique needs of cancer survivors and caregivers of cancer survivors. Due to the 
variance in prognoses and heterogeneity in age groups affected, diagnoses within these 
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categories, available treatment options, and financial burdens caused by leukemia and lymphoma, 
it is expected that the degree to which participants report post-traumatic growth will also vary 
widely. Past studies on posttraumatic growth in cancer survivors and their caregivers suggest that 
the severity of the diagnosis and health-related QOL will impact the level of posttraumatic 
growth experienced by participants following treatment. Previous studies suggest that the level 
of survivorship concerns might be higher among caregivers than LLS. However, few studies on 
cancer survivorship concerns and posttraumatic growth have been conducted since the 
administration of the Affordable Care Act. Perhaps this relationship will be attenuated now that 
the Affordable Care Act is in effect.  
The primary goal of this study is to investigate the impact of the diagnosis of a non-solid 
versus solid tumor, being a caregiver versus survivor of cancer, and the perceived severity of a 
cancer diagnosis across various domains implicated in cancer survivorship. This study will 
evaluate the following hypotheses: 1) a non-solid tumor diagnosis, being a cancer survivor, and a 
higher degree of perceived disease severity will predict higher scores on the Posttraumatic 
Growth Inventory; 2) higher scores on the Impact of Cancer Positive Impact Scale will be 
predicted by being a survivor versus a caregiver, a diagnosis of a non-solid versus a solid tumor, 
and a higher degree of perceived disease severity; 3) higher scores on the Impact of Cancer 
Negative Impact scale will be predicted by being a caregiver versus a survivor, a diagnosis of a 
non-solid versus a solid tumor, and a higher degree of disease severity; 4) survivors of non-solid 
tumors will endorse lower scores on the Center for Disease Control Health Related Quality of 
Life Healthy Days Index than survivors of solid tumors; and 5) caregivers and survivors of non-
solid tumors will endorse lower scores on the Oslo Social Support scale than caregivers and 
survivors of solid tumors 
 
 
21 
 
Chapter 2. Methods 
Participants  
Eighty adult cancer survivors and caregivers were recruited for this study. Twenty-nine 
participants were excluded due to not having completed any of the outcome questionnaire items, 
leaving 51 participants who were retained in the data analyses. Eligibility criteria included: either 
a previous diagnosis of cancer or a history of having assisted in caring for a cancer survivor, 
being at least 18 years of age, and residing in the United States. Research on posttraumatic 
growth in cancer survivors has used variable timeframes following their initial diagnosis in 
which they were recruited to participate (e.g. Zebrack et al., 2012, Rowlands et al., 2013). To 
increase the breadth of this study, time since diagnosis and/or treatment cessation was not 
restricted as part of the eligibility criteria. This projected sample-size was calculated using 
G*Power 3.1 (Faul, Erdfelder, Buchner, & Lang, 2009) with the effect-size estimate for a 
regression analysis of the impact of solid versus non-solid tumor diagnosis on posttraumatic 
growth. The effect-size estimation was based on calculations from the Cordova and colleagues 
(2001) study investigating posttraumatic growth among breast cancer survivors using the PTGI. 
The sample-size projection estimated that at least 49 participants would be required to obtain 
statistically significant results using linear regressions.  
Participants were recruited between October 23, 2017 and June 2, 2018 nationwide from 
various websites offering classified advertisements for research participation, including 
Craigslist, Reddit, and ClassifedAds.com and social media outlets for recruiting research 
participants (e.g. Swap Survey). Please see Appendix B for a list of locations in which 
advertisements were placed on Craigslist. Locations were selected based on the presence of a 
hospital recognized as a Center of Excellence in treating Leukemia and/or Lymphoma and/or 
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based on population size to maximize recruitment of LLS and their caregivers. Several 
organizations providing information and support for cancer survivors and caregivers were also 
contacted and requested to assist with recruitment (e.g. stupidcancer.org and CancerLiving 
Today), however, they declined to participate or did not respond. At the end of the questionnaire, 
participants were provided with a link to the survey and asked to share the link with members of 
their social media network, thereby allowing for snowball sampling. Participants were not 
required to be pairs of cancer survivors and caregivers, however with the use of snowball 
sampling as a recruitment technique, some of the caregivers may have provided care for the 
survivors in the sample.  Please see Appendix C for a copy of the advertisement placed on these 
websites. 
Measures 
 Demographic questions were asked to gather information on the sample make-up. These 
included solid vs. non-solid tumor diagnosis, the specific diagnosis, perception of cancer severity, 
recurrence or additional cancers since initial diagnosis, age, gender, and ethnicity. Such variables 
have been found in previous studies to be related to the level of post-cancer distress experienced 
by LLS (Jones et al., 2015; Parry et al., 2011; See the demographic questions in Appendices D 
and E). 
The Post Traumatic Growth Inventory (PTGI) is a 21-item questionnaire that utilizes a 6-
point Likert scale, from 0 = “I did not experience this change as a result of my crisis” to 5=I 
experienced this change to a very great degree as a result of my crisis” (Tedeschi & Calhoun, 
1995; See Appendices F and G). A composite score on the PTGI is obtained by summing 
responses to all of the items. The authors have uncovered the following five-factor structure: 
Factor 1: Relating to Others, Factor 2: New Possibilities, Factor 3, Personal Strength, Factor 4: 
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Spiritual Change, and Factor 5: Appreciation of Life (Tedeschi & Calhoun, 1995). Taku, Cann, 
Calhoun, and Tedeschi (2008) conducted a confirmatory analysis using a sample of traumatic 
event survivors to determine if the PTGI functioned best as a 5-factor model, 3-factor model, or a 
1-model. They found that a 5-factor model allowing correlations among the factors was the best 
fit.  
The PTGI has been tested with undergraduate college students (Baker, Kelly, Calhoun, 
Cann, & Tedeschi 2008; Morris, Shakespeare-Finch, Rieck, & Newbery, 2005; Shakespeare-
Finch & Enders, 2008; Tedeschi & Calhoun, 1995) and survivors of traumatic events (Taku et al., 
2008). It has shown good internal reliability (Cronbach’s α = .90; Baker et al., 2008; Tedeschi & 
Calhoun, 1995) and acceptable test-retest reliability over two months (r=.71; Tedeschi & 
Calhoun, 1995). The PTGI has been correlated with experiences of trauma (Shakespeare-Finch 
& Enders, 2008), post-traumatic stress (Morris et al., 2005), optimism, and extraversion 
(Tedeschi & Calhoun, 1995). There is some indication that scores indicating higher levels of 
posttraumatic growth are associated with higher severity of the trauma experienced (Tedeschi & 
Calhoun, 1995). Gender differences have been found in one study; with women reporting greater 
growth (Tedeschi & Calhoun, 1995) but no significant gender differences were found in another 
study (Baker et al., 2008). For the purposes of this study, the word “crisis” has been changed to 
“cancer” in the questionnaire instructions and items. This was done with the permission of the 
authors.  
The Impact of Cancer version 2 (IOCv2) is a 46-item questionnaire consisting of 
statements about the potential positive and negative changes that cancer survivors report 
following treatment (see Appendices H and I for the questionnaire and Appendix J for the 
scoring instructions; Zebrack, Ganz, Bernaards, Petersen, & Abraham, 2006). Items are 
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measured on a 5-point Likert scale, from Strongly Disagree to Strongly Agree. The IOCv2 is 
comprised of the following scales: Positive Impact of Cancer, Negative Impact of Cancer, 
Employment Concerns, Relationship Concerns (not partnered) and Relationship Concerns 
(partnered). Within the Positive Impact Scale, there are four subscales: Altruism and Empathy, 
Health Awareness, Meaning of Cancer, and Positive Self-Evaluation. The Negative Impact Scale 
contains the following subscales: Appearance Concerns, Body Change Concerns, Life 
Interferences, and Worry (Zebrack et al., 2006). The IOCv2 has been used with survivors of non-
Hodgkin lymphoma (Smith et al., 2010), breast cancer survivors in the United States (Crespi, 
Ganz, Petersen, Castillo, & Caan, 2008) and France (Blanchin et al., 2015), and endometrial 
cancer in the Netherlands (de Boer et al., 2015). An exploratory factor analysis and confirmatory 
factor analysis indicate that the 42 items that make up the Positive Impact Scale and the Negative 
Impact Scale load together using an oblique rotation to create an 8-factor solution, corresponding 
with the eight subscales (Crespi et al., 2008). This factor structure was upheld in a sample of 
non-Hodgkin lymphoma survivors (Smith et al., 2010). Two higher-order factors were found, 
which correspond to the two scales. The internal consistencies of each of the subscales are good, 
with Cronbach’s α ranging from .76 (Employment Concerns) to .89 (worry). As the construct of 
positive impact of cancer appears to be similar to posttraumatic growth in cancer at face value, it 
is expected that responses on the PTGI and the IOCv2 Positive Impact Scale will correlate highly 
with each other. Due to the association between more severe forms of cancer and higher 
posttraumatic growth (e.g., Ponto et al., 2010; Zebrak et al., 2012), it is possible that the other 
scales of the IOCv2 will positively correlate with the PTGI as well. A caregiver version of the 
IOCv2 was created by adding “my loved one” before each mention of cancer. Permission was 
obtained from the authors to make this change to the IOCv2.  
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The Center for Disease Health Related Quality of Life Healthy Days Questionnaire Core 
Module (CDC HRQoL) is a 14-item questionnaire that assesses the number of days over the past 
30 days that an individual has been affected by physical and/or mental health problems 
(Hennessy, Moriarty, Zach, Scherr, & Brackbill, 1994; see Appendix K for the CDC HRQoL). It 
consists of a Core Module (4-items), an Activities Limitations Module (5-items), and a 
Symptoms Module (5-items). It has been tested on patients and survivors of a variety of health 
conditions in the United States, including myleodysplastic syndromes (Sekeres et al., 2011), 
metabolic syndrome (Ford & Li, 2008), smoking (McClave, Dube, Strine, & Mokdad, 2009), and 
coronary heart disease (Ford et al., 2008). The CDC HRQoL Core Module is scored by 
calculating a summary index of unhealthy days by adding the number of days over the past 30 
that the individual endorsed having not good physical health and the number of days they 
endorsed having not good mental health (Centers for Disease Control and Prevention, 2000). The 
sum is then set to a maximum of 30 days. A Healthy Days Index was computed by subtracting 
the Unhealthy Days Index from 30, as recommended by the Centers for Disease Control (2000). 
There is no composite scoring system for the CDC-HRQoL Symptom Module, so each item was 
evaluated individually. The CDC HRQoL demonstrates good test-retest reliability after two 
weeks (r=.75 Andersen, Catlin, Wyrwich, & Jackson-Thompson, 2003). For the current study, 
the CDC HRQoL Core Module and Symptoms Module were administered as part of the battery 
assessing adjustment to cancer diagnoses among cancer survivors and their caregivers. 
The Oslo Social Support Scale (OSS-3) is a 3-item questionnaire designed to provide an 
efficient measure of social support available to participants across a range of international and 
interdisciplinary settings (Nosikov & Gudex, 2003). A composite score is obtained by summing 
the three items (Dalgard et al., 2006). See Appendix L for the OSS-3 and its scoring system. It 
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has found to predict risk for clinical depression among a large sample of participants from 
Finland, England, Ireland, Spain, and Norway (Dalgard et al., 2006). In a study of older persons 
living at home in Norway, social support as measured by the OSS-3 was found to mediate the 
relationship between psychological distress and somatic health problems (Bᴓen, Dalgard, & 
Bjertness, 2012).  
Procedure 
 All measures were administered online via Qualtrics. Informed consent was obtained 
prior to questionnaire administration. The study was piloted with two cancer survivors. Both 
indicated that the questionnaires took approximately 20 minutes in total to complete and did not 
seem burdensome. No significant concerns were raised about the questionnaires’ content by the 
volunteers who piloted the study or participants of the study.  
 The initial question presented asked if the participant was a cancer survivor, the caregiver 
of a cancer survivor, or both. Based on that answer, participants were directed to either the 
survivor or caregiver battery of questionnaires. Participants who endorsed being both survivors 
and caregivers were administered the survivor battery. The survivor battery consisted of the 
following questionnaires: the PTGI, the IOCv2, the CDC HRQoL-4, the CDC Healthy Days 
Symptom Module, the Oslo 3-item Social Support Scale, and a demographic questionnaire 
developed for the study. The caregiver battery consisted of the PTGI, the IOCv2 modified for 
caregivers, the CDC HRQoL Core Module, the CDC Healthy Days symptom module, the Oslo 
3-item Social Support Scale, and the caregiver version of the demographic questionnaire.  
Data Analyses 
Missing data mechanism was examined by applying Little’s (1988) test for missing 
completely at random (MCAR) using IBM SPSS Version 20. Only 5 participants (9.8%) 
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completed less than 50% of the items. The data were found to be MCAR for the PTGI 
(χ2=69.132, p=0.988), the IOCv2 (χ2=369.199, p=0.658), the HRQoL (χ2=43.097, p=0.227), the 
Oslo3 (χ2=2.043, p=0.360), and the variables related to participant characteristics (χ2=464.432, 
p=0.988). The percent of data missing ranged from 2% to 5.9% on the PTGI, 2% to 17.6% on the 
IOCv2, 9.8% to 17.6% on the CDC HRQoL, and 9.8% to 62.7% (income) for the participant 
characteristics variables. Under the assumption that the data is MCAR, any standard missing data 
handling technique would be appropriate (Enders, 2010), including listwise deletion, single 
imputation, and multiple imputation. For the current study, missing data was handled with 
multiple imputation in SPSS using 100 multiply-imputed datasets. This number of multiply-
imputed datasets was based on recommendations from Graham, Olchowski, and Gilreath (2007) 
to reduce the values for Standardized Error (SE) and the probability of false negative results. In 
the current study, the information obtained from observed data for the independent variables was 
limited. Therefore, in accordance with recommendations from Little (1992), data for the 
dependent and independent variables were imputed together to maximize the accuracy of the 
multiple imputations and the power for analyses based on the multiple imputations.  
Descriptive statistics were calculated to describe participant characteristics including: 
whether participants were caregivers or survivors, whether they/their loved ones were diagnosed 
with a solid versus a non-solid tumor, the perceived severity of their diagnosis, treatments 
received, age, gender, marital status, employment status, number of people living in their 
household, annual household income, estimated direct cost of cancer treatment, and estimated 
indirect costs of cancer/cancer treatment. For categorical variables, such as whether the 
participant was a survivor or a caregiver, whether they/their loved one was diagnosed with a 
solid or a non-solid tumor, the cancer treatments received, marital status, employment status, and 
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gender, the frequency and percentages of participants who endorsed each response category were 
reported. The mean, standard deviation, median, minimum value, and maximum value were 
reported for the quantitative variables, such as the number of people living in the home, annual 
household income, the estimated direct cost of cancer care, and the estimated indirect cost of 
cancer and cancer care. As these data was analyzed to describe the characteristics of the sample 
obtained, all results are reported using the original data prior to the multiple imputation with 
pairwise deletion of missing data. 
Descriptive statistics and were also conducted on the composite scores of PTGI, IOCv2, 
CDC HRQoL Healthy Days Index, the CDC HRQoL Symptom Module scores, and the OSS-3 
among caregiver and survivor subsamples to understand the degree to which participants 
endorsed items on each scale. These statistics include the means, standard deviations, medians, 
minimum values, and maximum values endorsed for each scale across the survivor and caregiver 
subgroups. T-tests were conducted to test the differences in mean scores between cancer survivor 
and caregiver subsamples. These data present descriptive statistics about the sample obtained, the 
results were reported using the original data prior to the multiple imputation with pairwise 
deletion of missing data. 
To demonstrate the reliability of the PTGI, IOCv2, CDC HRQoL Healthy Days Index, 
and the OSS3, Cronbach Alphas were calculated in both caregiver and survivor subgroups of the 
sample. For measures which Cronbach Alphas were similar, subsequent analyses utilized 
combined data from the caregiver and survivor subgroups. For measures which the Cronbach 
Alphas were substantially dissimilar among survivors and caregivers, analyses were separated 
for each group. All results from the multiply imputed datasets were pooled.  
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Two correlation matrices were constructed to investigate the relationships between the 
outcome measures: the PTGI, the IOCv2 Positive Impact Scale, the IOCv2 Negative Impact 
Scale, the CDC HRQoL Healthy Days Index, and the OSS3 among caregivers and survivors. The 
correlation matrices were calculated separately among the caregiver and survivor subsamples. 
The correlation matrices were separated to demonstrate the degree to which the caregiver and 
survivor subsamples experienced adjustment to cancer survivorship similarly and that the data 
from both groups could be analyzed together. All correlations are presented using pooled data 
from the multiple imputations.  
 To address hypothesis one, that a non-solid tumor diagnosis, being a cancer survivor, and 
a higher degree of perceived disease severity will predict higher scores on the PTGI, a multiple 
regression was conducted. Composite scores on the PTGI were set as the independent variable 
and the diagnosis of a solid versus non-solid tumor, whether the participants were cancer 
survivors or caregivers, and the degree of perceived severity were the predictor variables. Results 
from the multiply-imputed datasets were pooled. 
 The second hypothesis, that higher scores on the IOCv2 Positive Impact Scale will be 
predicted by being a survivor versus a caregiver, a diagnosis of a non-solid versus a solid tumor, 
and a higher degree of perceived disease severity, was assessed using a multiple regression. This 
regression utilized the composite scores on the IOCv2 Positive Impact Scale as the independent 
variable and the diagnosis of a solid versus non-solid tumor, whether participants were survivors 
or caregivers, and the degree of perceived severity as the predictor variables. The resulting t-tests 
are presented using pooled analyses from the multiply-imputed datasets. 
 To test the third hypothesis, that higher scores on the IOCv2 Negative Impact Scale will 
be predicted by being a caregiver versus a survivor, a diagnosis of a non-solid versus a solid 
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tumor, and a higher degree of disease severity, a third multiple regression was conducted. The 
composite scores on the IOCv2 Negative Impact Scale were set as the independent variable and 
the diagnostic category, being a caregiver versus a survivor, and the perceived severity of the 
cancer diagnosis were used as the predictor variables. Results from the multiply-imputed datasets 
were pooled.   
To address the fourth hypothesis, that survivors of non-solid tumors will endorse a lower 
level of health-related quality of life than survivors of solid tumors, a t-test was conducted 
evaluating the difference in mean composite scores on the CDC HRQoL Healthy Days Index 
between survivors of solid and non-solid tumors. The results from the multiply-imputed datasets 
were pooled. 
The final hypothesis, that caregivers and survivors of non-solid tumors will endorse 
lower levels of social support than caregivers and survivors of solid tumors, was assessed with 
two t-tests. The first t-test evaluated the differences in means on OSS-3 composite scores 
between survivors of solid versus non-solid tumors. The second t-test assessed differences in 
mean composite scores on the OSS-3 between caregivers of cancer survivors with solid versus 
non-solid tumors. The t-tests were presented using data pooled from the multiple imputations. 
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Chapter 3. Results  
Participants 
Participant characteristics are summarized in Tables 1-3. Table 1 demonstrates the 
proportions of each measured categorical demographic variable. Table 2 summarizes the 
descriptive statistics of the quantitative demographic and cancer/treatment-related variables. 
Table 3 describes the proportions of each measured cancer/treatment-related variables among 
participants in the sample. Of note, 56.9% of participants were cancer survivors and 43.1% were 
caregivers of cancer survivors. More participants had solid versus non-solid tumors (47.1% 
versus 31.3%). 
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Table 1 
Frequency and Percentages of Participants Endorsing Demographic Variables (Categorical) 
Demographic Variable Frequency Percentage 
   
Gender   
        Males 14 27.5% 
        Females 31 60.8% 
        Transgender   1   2.0% 
        Did not disclose   5   9.8% 
Ethnicity   
        Caucasian 36 70.6% 
        Asian   6 11.8% 
        African American   2   3.9% 
        Multi-ethnic   2   3.9% 
        Did not disclose   5   9.8% 
Insurance   
        No   3   5.9% 
        Yes 36 70.6% 
        Did not disclose 12 23.5% 
Employment status   
       Unemployed 22 43.1% 
       Employed part-time   3   5.9% 
       Employed full-time 18 35.3% 
       Did not disclose 8 15.7% 
Marital status   
       Married 17 33.3% 
       Cohabiting 10 19.6% 
       Single   6 11.8% 
       Divorced   9 17.6% 
       Widowed   1   2.0% 
       Did not disclose   8 15.7% 
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Table 2 
Descriptive Statistics of Quantitative Demographic and Disease/Treatment-Related Variables 
Variable N Mean Standard 
Deviation 
Median Range 
Age 45 49.71 15.35 53.0 24 – 77 
Number of people 
living in the house 
40   2.8   1.62   2.0   1 -   8 
Annual household 
income 
19   $97 315.79 $87 195.22 $73 000 $6000 - $305 000 
Direct out-of-pocket 
cost of treatment 
31 $16849.03 $32 227.30 $2000 $0 – $122 000 
Indirect out-of-pocket 
cost of 
cancer/treatment 
26 $123 400.00 $497 147.53 $0 $0 - $2 500 000 
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Table 3 
Frequency and Percentages of Participants Who Endorsed Disease and Treatment-Related 
Variables (Categorical) 
Variable Frequency Percentage 
Survivor vs. caregiver   
        Survivors 29 56.9% 
        Caregivers 22 43.1% 
Diagnosis   
        Solid tumor 24 47.1% 
        Leukemia   4   7.8% 
        Lymphoma 12 23.5% 
        Did not disclose 11 21.6% 
Perceived Severity   
        Not severe 2   3.9% 
        Slightly severe 7 13.7% 
        Moderately severe 16 31.4% 
        Very severe 7 13.7% 
        Extremely Severe 11 21.6% 
        Did not disclose 8 15.7% 
Recurrence   
        No 32 62.7% 
        Yes 9 17.6% 
        Did not disclose 10 19.6% 
Secondary Malignancy   
        No 36 70.6% 
        Yes 7 13.7% 
        Did not disclose 8 15.7% 
Treatment   
        Chemotherapy 28 54.9% 
        Radiation therapy 19 37.3% 
        Bone marrow transplant   1   2.0% 
        Watchful waiting   5   9.8% 
        Surgery 21 41.2% 
Treatment end date   
        Less than 1 year ago   3   5.9% 
        Greater than 1 year ago 22 43.1% 
        Still in treatment 13 25.5% 
        Deceased (for caregivers only)   2   3.9% 
        Did not disclose 11 21.6% 
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Descriptive statistics and t-tests for the questionnaire data 
 Caregivers (M = 68.31, SD = 26.14) of cancer survivors endorsed a higher level of 
posttraumatic growth on the PTGI than survivors (M = 57.58, SD = 21.79), however this 
difference was not significant at the p≤0.05 level (t(43) = 1.5, p = 0.14). There was a small, non-
significant difference in means between cancer survivors and caregivers on the IOCv2 Positive 
Impact Scale, with survivors (M = 59.63, SD = 10.03) reporting greater cancer-specific positive 
changes than caregivers (M = 54.54, SD = 11. 77, t(38) = -1.42, p = 0.16). Caregivers (M = 65.00, 
SD = 14.79) also endorsed higher scores on the IOCv2 Negative Impact Scale than survivors (M 
= 62.48, SD = 19.48), however this difference was also not statistically significant (t(41) = 0.45, 
p = 0.66). Cancer survivors (M = 17.18 SD = 11.11) reported slightly higher scores on the CDC 
HRQoL Healthy Days Index than caregivers (M = 16.28, SD = 10.86), although this difference in 
scores was not significant at the p≤0.05 level (t(44) = -0.27, p = 0.79). On the CDC HRQoL 
Symptom Module Pain question, survivors (M = 6.40, SD = 10.07) reported more days with pain 
over the past 30 days than caregivers (M = 4.83, SD = 8.11), however this difference was not 
statistically significant (t(41) = -0.55, p = 0.59). Survivors (M  = 9.36, SD = 9.47) also endorsed 
statistically non-significantly more days with depression on the CDC HRQoL Symptom Module 
Depression question than caregivers (M = 8.33, SD = 9.15, t(44) = - 0.36, p = 0.72). On the CDC 
HRQoL Symptom Module Anxiety question, survivors (M = 11.15, SD = 10.92) endorsed a non-
significantly greater amount of days that they experienced problematic anxiety than caregivers 
(M = 8.35, SD = 8.08, t(42) = -0.91, p = 0.37). Survivors (M = 12.44, SD = 9.12) also endorsed 
more days without sufficient sleep or rest than caregivers (M = 9.39, SD = 10.79) on the CDC 
HRQoL Symptom Module Sleeplessness question, although this difference was not significant 
(t(43) = -1.02, p = 0.31). Caregivers (M = 11.53, SD = 1.74) endorsed a significantly higher level 
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of social support than survivors on the OSS-3 (M = 9.68, SD = 3.14, t(43) = 2.23, p = 0.031). See 
Table 4. 
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Table 4 
Descriptive statistics for the PTGI, the IOCv2, the CDC HRQoL Healthy Days Index, the CDC 
HRQoL Symptom Module, and the OSS-3 among cancer survivors versus caregivers. 
Survivor/ 
Caregiver 
Variable N Mean SD Median Minimum/ 
Maximum 
t-test P 
Survivor PTGI 26 57.58 21.79 58.50 6 to 89   
Caregiver PTGI 19 68.31 26.14 71.00 19 to 105 1.50 0.14 
Survivor IOCv2 Positive Impact 
Scale 
27 59.63 10.03 61.00 39 to 76   
Caregiver IOCv2 Positive Impact 
Scale 
13 54.54 11.77 57.00 21 to 69 -1.42 0.16 
Survivor IOCv2 Negative Impact 
Scale 
27 62.48 19.48 59.00 26 to 93   
Caregiver IOCv2 Negative Impact 
Scale 
16 65.00 14.79 68.00 34 to 89 0.45 0.66 
Survivor CDC HRQoL Healthy 
Days Index 
28 17.18 11.11 21.00 0 to 30   
Caregiver CDC HRQoL Healthy 
Days Index 
18 16.28 10.86 20.00 0 to 30 -0.27 0.79 
Survivor CDC HRQoL Symptom 
Module Pain 
25   6.40 10.07   0.00 0 to 30   
Caregiver  CDC HRQoL Symptom 
Module Pain 
18   4.83   8.11   1.50 0 to 30 -0.55 0.59 
Survivor CDC HRQoL Symptom 
Module Depression 
28   9.36   9.47   5.50 0 to 30   
Caregiver CDC HRQoL Symptom 
Module Depression 
18   8.33   9.15   6.00 0 to 30 -0.36 0.72 
Survivor CDC HRQoL Symptom 
Module Anxiety 
27 11.15 10.92   8.00 0 to 30   
Caregiver CDC HRQoL Symptom 
Module Anxiety 
17   8.35   8.08   8.35 0 to 30 -0.91 0.37 
Survivor CDC HRQoL Symptom 
Module Sleeplessness 
27 12.44   9.12 10.00 0 to 30   
Caregiver CDC HRQoL Symptom 
Module Sleeplessness 
18   9.39 10.79   5.00 1 to 30 -1.02 0.31 
Survivor OSS-3 28   9.68   3.14 10.50 3 to 14   
Caregiver  17 11.53   1.74 12.00 9 to 14 2.23 0.031 
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Cronbach Alphas 
 In the current sample, the PTGI demonstrated excellent internal consistency overall 
(α=0.95) and for the survivor (α=91) and caregiver (α=0.98) subgroups. The IOCv2 Positive 
Impact scale showed good internal consistency overall (α=0.83) and for the survivor (α=0.80) 
caregiver (α=0.88) subgroups. Cronbach Alphas suggest that the IOCv2 Negative Impact scale 
demonstrated excellent internal consistency with the entire sample (α=0.91) and with the 
survivor subgroup (α=0.93), while the Cronbach Alpha fell within the good range for the 
caregiver group (α=0.877). The CDC HRQoL Healthy Days Index showed poor internal 
consistency across the overall sample (α=0.53), the survivor subgroup (α=0.49), and the 
caregiver subgroup (α=0.58). The OSS3 demonstrated fair internal consistency overall (α=0.75) 
but good internal consistency in the survivor subgroup (α=0.80) and poor internal consistency in 
the caregiver subgroup (α=0.50).  
Correlations 
The correlation matrices for the cancer survivor and caregiver subgroups displaying 
correlations between the composite scores on the outcome measures related to cancer 
survivorship are presented in Table 5. Among the cancer survivor subsample, the following 
correlations were statistically significant at the P ≤0.01 level: between composite scores on the 
PTGI and the IOCv2 Positive Impact Scale (r(27) = 0.73, p <0.001), the IOCv2 Negative Impact 
Scale and the CDC HRQoL Healthy Days index (r(27) = -0.58, p = 0.001), the IOCv2 Negative 
Impact Scale and the CDC HRQoL Symptom Module Depression score (r(27) = 0.57, p = 0.001), 
the CDC HRQoL Healthy Days Index and the CDC HRQoL Symptom Module Pain score (r(27) 
= -0.51, p = 0.004), the CDC HRQoL Healthy Days Index and the CDC HRQoL Symptom 
Module Depression score (r(27) = -0.69, p < 0.001), the CDC HRQoL Healthy Days Index and 
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the CDC HRQoL Symptom Module Anxiety score (r(27) = -0.57, p = 0.001), the CDC HRQoL 
Symptom Module Depression score and the CDC HRQoL Symptom Module Anxiety score 
(r(27) = 0.82, p<0.001), and the CDC HRQoL Symptom Module Depression score and the CDC 
HRQoL Symptom Module Sleeplessness score (r(27) = 0.51, p = 0.005). Correlations within the 
survivor subsample that reached the 0.05 level of significance were: between the IOCv2 
Negative Impact Scale and the CDC HRQoL Symptom Module Pain score (r(27) = 0.42, p = 
0.25), the IOCv2 Negative Impact Scale and the CDC HRQoL Symptom Module Anxiety Score 
(r(27) = 0.41, p = 0.025), the CDC HRQoL Healthy Days Index and the OSS-3 (r(27) = 0.40, p = 
0.032), the CDC HRQoL Symptom Module Pain score and the CDC HRQoL Symptom Module 
Depression Score (r(27) = 0.38, p = 0.045), CDC HRQoL Symptom Module Pain score and the 
CDC HRQoL Symptom Module Sleeplessness score (r(27) = 0.43, p = 0.018), CDC HRQoL 
Symptom Module Depression score and the OSS-3 (r(27) = -0.40, p = 0.032), and the CDC 
HRQoL Symptom Module Anxiety score and the CDC HRQoL Symptom Module Sleeplessness 
score (r(27) = 0.41, p = 0.029). Correlations among the cancer survivor subsample that were 
statistically non-significant included the correlation between the PTGI and the IOCv2 Negative 
Impact Scale (r(27) = 0.10, p = 0.62), the PTGI and the CDC Healthy Days Index (r(27) = -0.012, 
p = 0.95), the PTGI and the CDC HRQoL Symptom Module Pain score (r(27) = 0.032, p = 0.87), 
the PTGI and the CDC HRQoL Symptom Module Depression score (r(27) = 0.080, p = 0.68), 
the PTGI and the CDC HRQoL Anxiety score (r(27) = -0.10, p = 0.60), the PTGI and the CDC 
HRQoL Sleeplessness score (r(27) = 0.10, p = 0.61), the PTGI and the OSS-3 (r(27) = 0.17, p = 
0.38), the IOCv2 Positive Impact Scale and the IOCv2 Negative Impact Scale (r(27) = 0.052, p 
= 0.79), the IOCv2 Positive Impact Scale and the CDC HRQoL Healthy Days Index (r(27) = 
0.22, p = 0.25), the IOCv2 Positive Impact Scale and the CDC HRQoL Symptom Module Pain 
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score (r(27) = 0.038, p = 0.85), the IOCv2 Positive Impact Scale and the CDC HRQoL Symptom 
Module Depression score (r(27) = -0.15, p = 0.44), the IOCv2 Positive Impact Scale and the 
CDC HRQoL Symptom Module Anxiety score (r(27) = -0.33, p = 0.081), the IOCv2 Positive 
Impact Scale and the CDC HRQoL Symptom Module sleeplessness score (r(27) = -0.075, p = 
0.70), the IOCv2 Positive Impact Scale and the OSS-3 (r = 0.22, p = 0.70), the IOCv2 Negative 
Impact Scale and the CDC HRQoL Symptom Module Sleeplessness score (r(27) = 0.23, p = 
0.23), the IOCv2 Negative Impact Scale and the OSS-3 (r(27) = -0.20, p = 0.30), the CDC 
HRQoL Healthy Days Index and CDC HRQoL Symptom Module Sleeplessness score (r(27) = -
0.25, p = 0.19), the CDC HRQoL Symptom Module Pain score and the CDC HRQoL Symptom 
Module Anxiety score (r(27) = 0.27, p = 0.16), the CDC HRQoL Symptom Module Pain score 
the OSS-3 (r(27) = -0.011, p = 0.95), the CDC HRQoL Symptom Module Anxiety score and the 
OSS-3 (r(27) = -0.28, p = 0.15), and the CDC HRQoL Symptom Module Sleeplessness score 
and the OSS-3 (r(27) = -0.20, p = 0.30).  
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Table 5 
Correlation matrix for outcome variables related to adjustment to cancer among cancer 
survivors and caregivers. 
 PTGI IOCv2 
Positive 
Impact 
Scale 
IOCv2 
Negative 
Impact 
Scale 
CDC 
HRQoL 
Healthy 
Days 
Index 
CDC 
HRQoL 
Symptom 
Module: 
Pain 
CDC 
HRQoL 
Symptom 
Module: 
Depression 
CDC 
HRQoL 
Symptom 
Module: 
Anxiety 
CDC 
HRQoL 
Symptom 
Module: 
Sleeplessness 
OSS-3 
PTGI 1 0.73** 0.10 -0.012 0.032 0.080 -0.10 0.10 0.17 
IOCv2 
Positive 
Impact Scale 
0.75** 1 0.052 0.22 0.038 -0.15 -0.33 -0.075 0.22 
IOCv2 
Negative 
Impact Scale 
0.66** 0.74** 1 -0.58** 0.42* 0.57** 0.41* 0.23 -0.20 
CDC 
HRQoL 
Healthy Days 
Index 
-0.32 -0.31 -0.28 1 -0.51** -0.69** -0.57** -0.25 0.40* 
CDC 
HRQoL 
Symptom 
Module: Pain 
0.25 0.16 0.060 -0.62** 1 0.38* 0.27 0.43* -0.011 
CDC 
HRQoL 
Symptom 
Module: 
Depression 
0.31 0.32 0.15 -0.64** 0.50* 1 0.82** 0.51** -0.40* 
CDC 
HRQoL 
Symptom 
Module: 
Anxiety 
0.28 0.27 0.19 -0.62** 0.62** 0.83** 1 0.41* -0.28 
CDC 
HRQoL 
Symptom 
Module: 
Sleeplessness 
0.30 0.32 0.16 -0.78** 0.672** 0.78** 0.78** 1 -0.20 
OSS-3 -0.15 -0.37 -0.15 0.094 0.093 0.025 -0.033 0.015 1 
Note: the top diagonal of the table presents the correlation matrix for cancer survivors and the 
bottom diagonal presents the correlation matrix for caregivers of cancer survivors.  
* indicates that the correlation was significant at the 0.05 level 
** indicates that the correlation was significant at the 0.01 level 
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For the caregiver subgroup, correlations at the p≤0.01 level were found between the 
PTGI and the IOCv2 Positive Impact Scale (r(20) = 0.75, p <0.001), the PTGI and the IOCv2 
Negative Impact Scale (r(20) = 0.66, p = 0.001), the IOCv2 Positive Impact Scale and the IOCv2 
Negative Impact Scale (r(20) = 0.74, p <0.001), the CDC HRQoL Healthy Days Index and the 
CDC HRQoL Symptom Module Pain score (r(20) = -6.2, p = 0.002), the CDC HRQoL Healthy 
Days Index and the CDC HRQoL symptom Module Depression score (r(20) = -0.64 p = 0.001), 
the CDC Healthy Days Index and the CDC HRQoL Symptom Module Anxiety score (r(20) = -
0.62, p = 0.002), the CDC Healthy Days Index and the CDC HRQoL Symptom Module 
Sleeplessness score (r(20) = -0.78, p < 0.001), the CDC HRQoL Symptom Module Pain score 
and the CDC HRQoL Symptom Module Anxiety score (r(20) = 0.62, p = 0.002), the CDC 
HRQoL Symptom Module Pain score and the CDC HRQoL Symptom Module Sleeplessness 
score (r(20) = 0.67, p <0.001), the CDC HRQoL Symptom Module Depression score and the 
CDC HRQoL Symptom Module Anxiety score (r(20) = 0.83, p < 0.001), the CDC HRQoL 
Symptom Module Depression score and the CDC HRQoL Symptom Module Sleeplessness score 
(r(20) = 0.78, p < 0.001), and the CDC HRQoL Symptom Module Anxiety score and the CDC 
HRQoL Sleeplessness score (r(20) = 0.775, p < 0.001). The correlation between the CDC 
HRQoL Symptom Module Pain score and the CDC HRQoL Depression score (r(20) = 0.50, p = 
0.018) fell between the p = 0.05 and p = 0.01 significance levels among the caregiver subsample. 
Correlations between the following variables were not found to be significant below the p ≤ 0.05 
significance level in the caregiver subsample: the PTGI and the CDC HRQoL Healthy Days 
Index (r(20) = -0.32, p = 0.16), the PTGI and the CDC HRQoL Symptom Module Pain score 
(r(20) = 0.25, p = 0.28), the PTGI and the CDC HRQoL Symptom Module Depression score 
(r(20) = 0.31, p = 0.16), the PTGI and the CDC HRQoL Symptom Module Anxiety score (r(20) 
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= 0.28, p = 0.21), the PTGI and the CDC HRQoL Symptom Module Sleeplessness score (r(20) = 
0.30, p = 0.18), the PTGI and the OSS-3 (r(20) = -0.15, p = 0.53), the IOCv2 Positive Impact 
Scale and the CDC HRQoL Healthy Days Index (r(20) = -0.31, p = 0.16), the IOCv2 Positive 
Impact Scale and the CDC HRQoL Symptom Module Pain score (r(20) = 0.16, p = 0.47), the 
IOCv2 Positive Impact Scale and the CDC HRQoL Symptom Module Depression score (r(20) = 
0.32, p = 0.15), the IOCv2 Positive Impact Scale and the CDC HRQoL Symptom Module 
Anxiety score (r(20) = 0.27, p = 0.23), the IOCv2 Positive Impact Scale and the CDC HRQoL 
Symptom Module Sleeplessness score (r(20) = 0.32, p = 0.16), the IOCv2 Positive Impact Scale 
and the OSS-3 (r(20) = -0.37, p = 0.10), the IOCv2 Negative Impact Scale and the CDC HRQoL 
Healthy Days Index (r(20) = - 0.28, p = 0.22), the IOCv2 Negative Impact Scale and the CDC 
HRQoL Symptom Module Pain score (r(20) = 0.060, p = 0.79), the IOCv2 Negative Impact 
Scale and the CDC HRQoL Symptom Module Depression score (r(20) = 0.15, p = 0.51), the 
IOCv2 Negative Impact Scale and the CDC HRQoL Symptom Module Anxiety score (r(20) = 
0.19, p = 0.40), the IOCv2 Negative Impact Scale and the CDC HRQoL Symptom Module 
Sleeplessness score (r(20) = 0.16, p = 0.48), the IOCv2 Negative Impact Scale and the OSS-3 
(r(20) = -0.15, p = 0.53), the CDC HRQoL Healthy Days Index and the OSS-3 (r(20) = 0.094, p 
= 0.68), the CDC HRQoL Symptom Module Pain score and the OSS-3 (r(20) = 0.093, p = 0.69), 
the CDC HRQoL Symptom Module Depression score and the OSS-3 (r(20) = 0.025, p = 0.91), 
the CDC HRQoL Symptom Module Anxiety score and the OSS-3 (r(20) = -0.033, p = 0.89), and 
the CDC HRQoL Symptom Module Sleeplessness score and the OSS-3 (r(20) = 0.015, p = 0.95). 
Correlations between the CDC HRQoL Healthy Days Index and the OSS-3, the CDC 
HRQoL Symptom Module Depression score and the OSS-3, the IOCv2 Negative Impact Scale 
and the CDC HRQoL Healthy Days Index, the IOCv2 Negative Impact Scale and the CDC 
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HRQoL Symptom Module Pain score, the IOCv2 Negative Impact Scale and the CDC HRQoL 
Symptom Module Depression score, and the IOCv2 Negative Impact Scale and the CDC HRQoL 
Symptom Module Anxiety score were significant at the p ≤ 0.05 level among cancer survivors 
but not among caregivers of cancer survivors. The correlations between the PTGI and the IOCv2 
Negative Impact Scale and between the IOCv2 Positive Impact Scale and IOCv2 Negative 
Impact Scale were significant at the p ≤ 0.05 level among caregivers but not among cancer 
survivors. Based on these results and the Cronbach Alphas, the cancer survivor and caregiver 
subsamples demonstrate substantial differences and data for the hypothesis testing analyses will 
be analyzed separately for each subsample group. 
Hypotheses testing 
 The results from the multiple regression testing hypothesis one, that a non-solid tumor 
diagnosis, being a cancer survivor, and a higher degree of perceived disease severity will predict 
higher scores on the PTGI, did not find any of the proposed predictor variables significantly 
predicted PTGI composite scores. As the cancer survivor and caregiver subsamples were 
associated with different Cronbach Alphas and correlations for several of the measures, separate 
regressions were completed for each subsample and the survivor versus caregiver predictor 
variable was removed from the analyses. In the survivor group, neither solid versus non-solid 
tumor diagnosis (β = 5.30, t(28) = 0.57, p = 0.57) nor the perceived severity of the cancer 
diagnosis (β = 0.14, t(28) = 0.035, p = 0.97) significantly predicted PTGI scores. Solid versus 
non-solid tumor diagnosis (β = 8.83, t(21) = 0.58, p = 0.56) and the perceived severity of the 
cancer diagnosis (β = 0.92, t(21) = 0.16, p = 0.87) also did not predict PTGI scores among 
caregivers (see Table 6).  
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Table 6 
 
Multiple regression based on hypothesis 1 testing whether PTGI summary scores were predicted 
by a solid versus non-solid diagnosis and the perceived severity of the cancer diagnosis among 
cancer survivor and caregiver subsamples. 
 
 Survivors Caregivers 
Predictors  Β  SE β  t-test  p  β  SE β  t-test  p 
(Constant) 56.25 12.92 4.35 <0.001 60.09 24.34 2.47 0.014 
Solid versus non-solid tumor 
diagnosis 
  5.30   9.28 0.57  0.57 8.83 15.19 0.58 0.56 
Perceived severity of diagnosis   0.14   3.95  0.035 0.97  0.92   5.62 0.16 0.87 
 
 Hypothesis two, that higher scores on the IOCv2 Positive Impact Scale would be 
predicted by being a survivor versus a caregiver, a diagnosis of a non-solid versus a solid tumor, 
and a higher degree of perceived disease severity, was also not supported. The survivor versus 
caregiver predictor variable was also dropped from these analyses and the data was analyzed 
separately for cancer survivors and caregivers due to dissimilar Cronbach Alphas and 
correlations between outcome variables among survivors and caregivers. In the survivor group, a 
solid versus non-solid tumor diagnosis (β = 0.47, t(28) = 0.11, p = 0.91) and the perceived 
severity of the cancer diagnosis (β = 0.78, t(28) = 0.42, p = 0.68) did not significantly predict 
scores on the IOCv2 Positive Impact Scale. Neither a solid versus non-solid diagnosis (β = 0.26, 
t(21) = 0.038, p = 0.97) nor the perceived severity of the cancer diagnosis (β = -1.74, t(21) = -
0.72, p = 0.47) significantly predicted scores on the IOCv2 Positive Impact Scale (see Table 7). 
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Table 7  
 
Multiple regression based on hypothesis 2 testing whether the IOCv2 Positive Impact Scale 
summary scores were predicted by a solid versus non-solid tumor diagnosis and the perceived 
severity of the cancer diagnosis among cancer survivors and caregivers.  
 
 Survivors Caregivers 
Predictors  β SE β  t-test  p  Β  SE β t-test  P 
(Constant) 57.14 6.10 9.37 <0.001 61.39 10.55 5.82 <0.001 
Solid versus non-solid tumor 
diagnosis 
  0.47 4.31 0.11    0.91   0.26   6.83 0.038   0.97 
Perceived severity of diagnosis   0.78 1.86 0.42 0.68  -1.74   2.43   -0.72    0.47 
 
 The results from the multiple regression testing hypothesis three, that higher scores on the 
Impact of Cancer Negative Impact scale would be predicted by being a caregiver versus a 
survivor, a diagnosis of a non-solid versus a solid tumor, and a higher degree of disease severity, 
were also not statistically significant. These analyses were also conducted separately for the 
caregiver and survivor groups and the caregiver versus survivor predictor variable was dropped 
from the analyses due to discrepant Cronbach Alphas and correlations among outcome variables 
between caregivers and survivors. A diagnosis of a solid versus a non-solid tumor (β = 11.03, 
t(28) = 1.34, p = 0.18) and the perceived severity of the cancer diagnosis (β = 0.85, t(28) = 0.24, 
p = 0.81) did not predict scores on the IOCv2 Negative Impact Scale for cancer survivors. In the 
caregiver group, neither a diagnosis of a solid versus non-solid tumor (β =6.20, t(21) = 0.87, p = 
0.38) nor the perceived severity of the cancer diagnosis (β = 0.85, t(21) = -0.47, p = 0.64, see 
Table 8) predicted scores on the IOCv2 Negative Impact Scale. 
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Table 8 
Multiple regression based on hypothesis 3 testing whether the IOCv2 Negative Impact Scale 
summary scores were predicted by a solid versus non-solid tumor diagnosis and the perceived 
severity of the cancer diagnosis among cancer survivors versus caregivers. 
 
 Survivor Caregiver 
Predictor  Β  SE β  t-test  p  Β  SE β  t-test  p 
(Constant) 57.42 11.51 4.99 <0.00 65.61 11.37 5.77 <0.001 
Solid versus non-solid tumor 
diagnosis 
11.03   8.26 1.34    0.18   6.20   7.13 0.87 0.38 
Perceived severity of diagnosis   0.85   3.51 0.24    0.81 -1.23   2.60 -0.47 0.64 
         
  
 The t-test examining hypothesis four, that survivors of non-solid tumors would endorse a 
lower level of health-related quality of life than survivors of solid tumors, did not support this 
hypothesis. The t-test value of 0.162, p = 0.871 fell below the p ≤ 0.05 level of significance.  
 The analyses for the fifth hypothesis, that caregivers and survivors of non-solid tumors 
will endorse lower levels of social support than caregivers and survivors of solid tumors, did not 
show a significant difference in social support endorsed by diagnostic category in either 
subgroup. The t-tests comparing the means between cancer survivors diagnosed with solid versus 
non-solid tumors (t(21) = 1.17, p = 0.24) and comparing the means between caregivers of cancer 
survivors diagnosed with solid versus non-solid tumors (t(28) = -0.076, p = 0.94) did not reach 
the p ≤ 0.05 level of significance.  
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Chapter 4. Discussion 
Summary of results and implications 
 The primary purpose of this study was to investigate the potential impact of a diagnosis 
of a non-solid versus solid tumor and the perceived severity of a cancer diagnosis on several 
measures related to biopsychosocial adjustment to cancer and its treatment among cancer 
survivors and caregivers. Cronbach Alphas indicated that the OSS-3, the measure of social 
support utilized in this study, demonstrated good internal consistency among survivors but fair 
internal consistency among caregivers. This may have contributed to findings from the 
correlation matrix that the OSS-3 was significantly positively correlated with overall health-
related QOL and negatively correlated with depression among survivors but not caregivers. The 
OSS-3 scores could also moderate the relationships between various domains related to cancer 
survivorship and caregiving, although mediation analysis is beyond the scope of this study.  
The IOCv2 Negative Impact Scale was significantly negatively correlated with the CDC 
HRQoL Healthy Days Index and positively correlated with the CDC HRQoL Symptom Module 
pain, depression, and anxiety questions for survivors but not for caregivers. This could 
potentially be because for many cancer survivors, health problems captured by these measures of 
health related QOL are directly caused by the sequalae of cancer and its treatment (e.g. Parry et 
al., 2004; Jones et al., 2015), however direct relationships between cancer care and such health 
problems are less likely for caregivers. Another potential explanation for the differences in 
relationships between negative impacts of cancer and health related QOL is that the IOCv2, 
which was modified for caregivers from the cancer survivor version for this study, may not have 
accurately measured the unique experiences of caregivers. Among caregivers, the IOCv2 
Negative Impact Scale scores were significantly correlated with scores on the PTGI and IOCv2 
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Positive Impact Scale, which further indicated that there might be notable differences in 
adjustment to cancer among caregivers and survivors and/or measurement issues. As a result, the 
data for caregivers and survivors was analyzed separately to test the hypotheses.  
There were five hypotheses for this study. The first three evaluated whether a diagnosis 
of a solid versus non-solid tumor or the perceived severity of the cancer diagnosis predicted 
scores on the PTGI, the IOCv2 Positive Impact Scale, and the IOCv2 Negative Impact Scale 
among cancer survivors and caregivers. Neither the diagnosis of a solid versus non-solid tumor 
nor the perceived severity of the cancer diagnosis predicted scores on the outcome measures 
among the cancer survivor or caregiver group. However, this is likely, in part, due to the small 
sample size used in this study. As the sample size was split between cancer survivors and 
caregivers post hoc based on the results of the reliability analyses and correlation matrices, it was 
particularly small, which reduced the power to detect significant results. The t-test value 
assessing the diagnosis of a solid versus non-solid tumor as a predictor variable for composite 
scores on the IOCv2 Negative Impact Scale among survivors approached significance in this 
small sample. This may have emerged as a significant predictor of IOCv2 Negative Impact Scale 
scores with a larger sample. The other t-test values were small and would potentially require a 
much larger sample to demonstrate significant effects of a solid versus non-solid tumor diagnosis 
or the perceived severity of the cancer diagnosis on PTGI or IOCv2 composite scores.  
Several studies found that increased medical severity of cancer diagnoses were associated 
with higher levels of posttraumatic growth (e.g. Barakat et al., 2005, Ponto et al., 2010). While 
the current study was not able to assess medical severity of participants’ and/or their loved ones’ 
cancer diagnoses, participants’ perceptions of the severity of their/their loved ones’ cancer 
diagnoses did not appear to predict posttraumatic growth. Several studies have found that cancer 
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survivors’ perception of the severity of their cancer often does not match their medical providers’ 
understanding of the severity of their cancer (e.g. El-Jawahri et al., 2017; Shimer et al., 2018). 
Other studies have suggested that the physical impact of cancer and its treatment, including 
neuropathy and fatigue, can last for years following diagnosis (e.g. Parry et al., 2011; Jones et al., 
2015). It is possible that the physical severity of the cancer diagnoses predicts posttraumatic 
growth to a greater degree than perceived severity. This possibility would fit with the hypothesis 
that posttraumatic growth functions to facilitate adjustment to new life circumstances among 
individuals who have experienced trauma (Zoellner & Maercker, 2006). However, since the 
current study utilized self-reported outcome measures assessing perceived biopsychosocial 
changes due to cancer and its treatment, it would be expected that the perceived severity of 
cancer would be a stronger predictor of scores on these measures than the medical severity of 
their diagnoses.  
As the time since diagnosis and treatment cessation were not standardized as an inclusion 
criterion for this study, another possible explanation for the result that perceived severity of the 
diagnosis did not predict posttraumatic growth is that perceived severity of the diagnosis could 
mean different things to participants. Some participants were still in treatment and/or had not 
achieved remission during the study. For these participants, the perceived severity of their 
diagnosis may have reflected the perceived severity of their current symptoms and level of 
functioning. Other participants had been in remission for years and the perceived severity of their 
diagnosis might have reflected their past experiences with cancer that they had overcome. 
Previous studies have indicated that the levels of posttraumatic growth endorsed by cancer 
survivors varies based on the time since diagnosis (Rowlands et al., 2013; Zebrack et al., 2012). 
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It is possible that time since diagnosis and/or treatment cessation moderates the relationship 
between posttraumatic growth and the perceived severity of the cancer diagnosis.  
While this study investigated the impact of a non-solid tumor diagnosis on adjustment to 
cancer as a proxy for the unique challenges that LLS often face, such as the rarity of specific 
diagnoses and the likelihood of recurrence, these challenges are not necessarily universal to LLS 
and their caregivers. For example, the diagnosis of Hodgkin’s lymphoma is more common than 
certain solid tumors, such as renal cell carcinoma (Leukemia and Lymphoma Society, 2014) and 
is curable with chemotherapy (Girinsky et al., 2006). Few participants in the current study 
provided information about their specific cancer diagnoses, beyond leukemia, lymphoma, or a 
solid tumor. It is possible that the diagnosis of a solid versus non-solid tumor did not 
significantly predict scores on the PTGI and the IOCv2 partially because the general diagnosis of 
a solid versus non-solid tumor was not an accurate estimation of these challenges. Perhaps 
understanding of the diagnosis, the availability of resources to address biopsychosocial needs 
following a cancer diagnosis, and the likelihood of recurrence would be better predictors of 
scores on these measures than generally a solid versus non-solid tumor diagnosis.  
The fourth hypothesis investigated the differences in mean CDC HRQoL Healthy Days 
Index scores between survivors of solid versus non-solid tumors. The t-test value for this 
analysis was small and non-significant, indicating that it is unlikely that health related QOL was 
significantly different for survivors of solid versus non-solid tumors in this sample. This is 
somewhat unexpected given the increased rates of recurrence and greater heterogeneity of 
diagnoses classified as non-solid tumors versus solid tumors. It is possible the medical severity 
of the diagnosis and the time since treatment cessation could moderate this result. Other health-
related comorbidities were not assessed in the current study and have been found to impact 
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health-related QOL in another study of cancer survivors (Park and Blank, 2012). The presence of 
such comorbidities might also moderate possible differences in health-related QOL among 
survivors of solid versus non-solid tumors. Alternatively, as many of the participants were at a 
higher than expected income level, this lack of significant difference between health related QOL 
among survivors of solid versus non-solid tumors may represent a more homogeneous level of 
access to health care and prevention services. 
The fifth hypothesis addressed differences in mean levels of social support endorsed by 
caregivers and survivors of solid versus non-solid tumors. Although the t-tests assessing these 
differences were non-significant for both the caregiver and survivor groups, the t-test value for 
the survivor group was large enough that it may have been significant with a larger sample size, 
with survivors of non-solid tumors reporting non-significantly higher levels of social support 
than survivors of solid tumors. Whether there is truly no significant difference between social 
support among survivors of solid versus non-solid tumors or if this non-significantly higher level 
of social support endorsed by survivors of non-solid versus solid tumors would be significant 
with a larger sample size, this finding is unexpected. Several researchers have proposed that the 
heterogeneity of non-solid tumor diagnoses might lead to higher levels of social isolation among 
survivors of these diagnoses, compared to survivors of more homogeneous and/or common solid 
tumors (Jones et al., 2015; Parry et al., 2011). The results from the current study do not support 
this assertion and suggest that survivors of non-solid tumors may be able to compensate for the 
decreased availability of support from other survivors of their diagnosis in maintaining their 
support networks. Alternatively, as the OSS-3 is a brief and broad measure of social support, it is 
possible that it did not fully tap into the facets of social support that have been hypothesized in 
past studies to be lower among survivors of solid versus non-solid tumors. The rarity of the 
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specific solid and non-solid tumor diagnoses of the participants in this study may have also 
confounded these results. The t-test value in the caregiver group was small, which may have 
been partially an artifact of the internal consistency of the OSS-3 being low among caregivers in 
this sample.  
Strengths 
 This study was the first to examine the association between solid and non-solid tumor 
types on psychosocial adjustment to cancer. It was also one of a small number of studies to look 
at the psychosocial adjustment of cancer among caregivers. No published study to date has 
investigated the impact of perceived severity of cancer diagnoses on adjustment to cancer. 
The breath of the data collected regarding adjustment to cancer allowed for analysis of 
adjustment to cancer diagnoses in a variety of domains, including positive and negative 
psychosocial changes, posttraumatic growth, quality of life, and social support. This facilitated a 
greater understanding of the relationship between adjustment to cancer among these domains. 
Furthermore, the breadth of information collected on participant characteristics facilitated more 
comprehensive analyses of the impact that clinical and demographic characteristics could 
potentially have on various domains of adjustment to cancer diagnoses.  
By utilizing an online method of data collection, a diagnostically diverse national sample 
was able to be obtained. Despite research suggesting that online samples tend to capture younger 
participants at a greater rate than older participants (Kaplowitz, Hadlock, and Levine, 2004), this 
study recruited participants across a diverse range of ages. As participants were recruited 
primarily from online classified advertisements, rather than from websites geared towards 
providing information and support to cancer survivors and caregivers, it is possible that they 
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were more neutral than individuals actively seeking support and information on survivorship. 
Since the study was completed online, it may have been less of a burden to participate in than in-
person studies, which could have increased the rate of participation among cancer survivors who 
were more physically impaired than in-person studies tend to include.  
Limitations 
 The sample size from this study was small, which may have increased the possibility of 
false-negative findings. Outside of the medical system, this population was difficult to reach and 
it was hard to obtain a larger number of participants. Several of the results obtained, notably the 
multiple regression used to test hypothesis three among cancer survivors and the t-test used to 
evaluate hypothesis five, showed values that were large enough that they might demonstrate 
statistically significant results with a larger sample size.  While using an anonymous online 
convenience sample allowed us to obtain a geographically broader national sample of cancer 
survivors and caregivers, there were a number of limitations inherent in this type of sample. 
Most studies on cancer survivors and caregivers recruited participants from hospitals and thus 
were able to utilize data from the participants’ medical records to confirm participant 
characteristics, such as the diagnosis and treatments (e.g. Jones et al., 2015; Kim et al., 2010). As 
this data was not available for the current study, it is possible that participants’ recollection of 
their/their loved ones’ diagnoses, perceived severity, and treatments were not accurate or were 
missing due to a limited understanding of these variables and the diverse range of the amount of 
time that passed since their initial diagnosis/treatment.  
The mean and median income levels of participants who disclosed their income on the 
demographic questionnaire was much higher than the national average income. The majority of 
 
 
55 
 
participants did not disclose their income levels; however, it seems that participants at higher 
income levels were overrepresented in this study. The median household income of cancer 
survivors and caregivers in the United States is unknown. As cancer care is very expensive, it is 
possible that the high household income levels reported in the study are representative and 
potentially point towards people at higher levels of household income receiving better cancer-
related outcomes, which would increase the likelihood that they could participate in the study. 
Alternatively, this finding could represent a sampling bias and/or a bias in reporting household 
income.  
Due to concerns of the questionnaires being completed by automated computerized 
software, we did not compensate participants for their participation in this study. While this may 
have protected the data from including such automated responses, it may have introduced 
sampling bias into the study. People who chose to participate in an unpaid online study may have 
been more likely to have been at a higher income level and retired/working fewer hours than 
people who declined to participate. Since this study required internet access to participate, people 
at low income levels might have been less likely to participate due to limited internet access. As 
there was no monetary incentive to participate in this study, participants may have been 
motivated by a strong interest in cancer survivorship and/or caregiving for cancer survivors. 
They may have had more intense perceptions about the positive and negative biopsychosocial 
changes due to cancer.  
The IOCv2 was initially designed for cancer survivors and demonstrates good 
psychometric properties among cancer survivors (e.g. Zebrack et al., 2006; Crespi et al., 2008; 
Smith et al., 2010). However, it was modified for the current study for caregivers and has not 
been thoroughly psychometrically evaluated as a measure of biopsychosocial changes associated 
 
 
56 
 
with being a caregiver of a cancer survivor. The wording of the questionnaire items was 
minimally changed for caregivers and it is unknown whether this questionnaire truly assesses 
common biopsychosocial changes that caregivers experience when their loved one is diagnosed 
with cancer.  
Future Directions  
 As the small sample size was a major limitation in this study, in part due to the online 
recruitment strategy, it is recommended that future studies in the area of adjustment to cancer 
diagnoses be conducted with partnership with medical systems to increase access to participants. 
Recruiting participants through medical systems could also assist researchers in reimbursing 
participants while minimizing the risk of obtaining fraudulent responses from automated 
software. This may increase participation among caregivers and survivors at lower levels of 
social economic status.  
The statistically significant correlations among the standardized questionnaires indicate 
that the relationships between various domains of adjustment to cancer survivorship among 
survivors and caregivers may be more complex than originally hypothesized. Mediation analyses 
using structural equation modeling (SEM) may provide a better understanding of the interactions 
between these domains. This could broaden our understanding of the mechanisms by which we 
can help cancer survivors and their caregivers to increase positive biopsychosocial changes 
following cancer diagnoses while meeting ongoing biopsychosocial needs. SEM investigating 
the relationship between different domains of cancer survivorship is beyond the scope of this 
study. Such analyses will be completed in a follow-up study. This will require a larger sample 
size and further data collection is currently underway. 
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 More research is needed on assessing positive and negative biopsychosocial changes in 
caregivers following their loved ones’ cancer diagnosis to understand how cancer impacts the 
lives of caregivers and how to best support caregivers. The psychometric properties of the IOCv2 
could be tested in future research or alternatively, a separate tool specifically designed to 
measure biopsychosocial changes related to providing care for a loved one with cancer could be 
developed and evaluated. It is possible that some of the most pertinent concerns among 
caregivers of cancer survivors are unique to caregivers and are not addressed in the IOCv2.  
Conclusions 
 Cancer survivorship and caregiving for cancer survivors has been found to be related to a 
number of positive and negative biopsychosocial changes in several populations of cancer 
survivors and caregivers. Survivors of leukemia and lymphoma and their caregivers may face a 
particularly unique set of circumstances in that these diagnoses are very heterogeneous, and the 
probability of recurrence is often higher than it is for survivors of solid tumors. This study 
addressed five hypotheses related to differences in biopsychosocial adjustment to cancer among 
survivors and caregivers of solid versus non-solid tumors and by the perceived severity of cancer 
diagnoses. The results did not suggest that a solid versus non-solid tumor or the severity of 
cancer diagnoses predicted positive or negative biopsychosocial changes related to cancer or 
were associated with differences in mean indicators of health-related QOL or social support 
among survivors or caregivers. However, the sample size for the study was small and may have 
yielded false-positive findings in some of the analyses. The diagnoses of solid versus non-solid 
tumors and the perceived severity of cancer diagnoses may not be sufficient information to 
significantly predict the degree to which survivors and caregivers experience positive and 
negative biopsychosocial changes due to cancer. More research is needed to clarify the potential 
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relationships between cancer diagnoses, perceptions of cancer severity and biopsychosocial 
changes experienced by cancer survivors and caregivers due to cancer and its treatment.  
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Appendices 
Appendix A 
List of Non-Hodgkin Lymphoma Subtypes  
Subtype of Non-Hodgkin Lymphoma 
Myeloid and lymphoid neoplasms 
With eosinophilia and abnormalities of PDGFRA 
With eosinophilia and abnormalities of PDGFRB 
With eosinophilia and abnormalities of FGFR1 
Lymphoid neoplasms 
B Lymphoblastic leukemia/lymphoma, not otherwise specified (NOS) 
B lymphoblastic leukemia/lymphoma with recurrent genetic abnormalities 
B lymphoblastic leukemia/lymphoma with t(9:22)(q34;q11.2); BCR-ABL1 
B lymphoblastic leukemia/lymphoma with t((v;11q23); MLL rearranged 
B lymphoblastic leukemia/lymphoma with t(12;21)(p13;q22); TEL-AML1 (ETV6-
RUNX1) 
B lymphoblastic leukemia/lymphoma with hyperdiploidy 
B lymphoblastic leukemia/lymphoma with hypodiploidy (Hypodiploid ALL) 
B lymphoblastic leukemia/lymphoma with t(5;14)(q31;q32); IL3-IGH 
B lymphoblastic leukemia/lymphoma with t(1;19)(q23;p13.3); E2A-PBX1(TCF3-
PBX1) 
T lymphoblastic leukemia/lymphoma 
Mature B-cell neoplasms 
Chronic lymphocytic leukemia/small lymphocytic lymphoma 
Splenic marginal zone lymphoma 
Splenic B-cell lymphoma/leukemia, unclassifiable 
Splenic diffuse red pulp small B-cell lymphoma 
Lymphoplasmacytic lymphoma 
Heavy chain disease 
Alpha heavy chain disease 
Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT 
lymphoma) 
Nodal marginal zone lymphoma 
Follicular lymphoma 
Primary cutaneous follicle center lymphoma 
Mantle cell lymphoma 
Diffuse large B-cell lymphoma (DLBCL), NOS 
T cell/histiocyte-rich large B-cell lymphoma 
Primary DLBCL of the CNS 
Primary cutaneous DLBCL, leg type 
Subtype of Non-Hodgkin Lymphoma (cont.) 
EBV positive DLBCL of the elderly 
DLBCL associated with chronic inflammation 
Lymphomatoid granulomatosis 
Primary mediastinal (thymic) large B-cell lymphoma 
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Intravascular large B-cell lymphoma 
ALK positive large B-cell lymphoma 
Plasmablastic lymphoma 
Large B-cell lymphoma arising in HHV8-assoicated multicentric Castleman disease 
Primary effusion lymphoma 
Burkitt lymphoma 
B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and 
Burkitt lymphoma 
B-cell lymphoma, unclassifiable, with features intermediate between DLBCL and 
classical Hodgkin lymphoma 
Mature T-and NK-cell neoplasms 
Chronic lymphoproliferative disorder of NK cells 
Ebstein-Barr virus (EBV) positive T-cell lymphoproliferative diseases of childhood 
Systemic EBV+ T-cell lymphoproliferative diseases of childhood 
Hydroa vacciniforme-like lymphoma 
Adult T-cell leukemia/lymphoma 
Extranodal NK/T-cell leukemia/lymphoma 
Enteropathy-associated T-cell lymphoma 
Hepatosplenic T-cell lymphoma 
Subcutaneous panniculitis-like T-cell lymphoma 
Mycosis fungoides 
Sézary syndrome 
Primary cutaneous CD30 positive T-cell lymphoproliferative disorders 
Primary cutaneous peripheral T-cell lymphomas, rare subtypes 
Primary cutaneous gamma-delta T-cell lymphoma 
Primary cutaneous CD8 positive aggressive epidermotropic cytoxic T-cell lymphoma 
Primary cutaneous CD4 positive small/medium T-cell lymphoma 
Peripheral T-cell lymphoma, NOS 
Angioimmunoblastic T-cell lymphoma 
Anaplastic large cell lymphoma, ALK positive 
Anaplastic large cell lymphoma, ALK negative 
Immunodeficiency-associated lymphoproliferative disorders 
Lymphoproliferative diseases associated with primary immune disorders 
Lymphomas associated with HIV infection 
Post-transplant lymphoproliferative disorders (PTLD) 
Plasmacytic hyperplasia and infectious-mononucleosis-like PTLD 
Polymorphic PTLD 
Subtype of Non-Hodgkin Lymphoma (cont.) 
Monomorphic PTLD 
Other iatrogenic immunodeficiency-associated lymphoproliferative disorders 
Histiocytic and dendritic cell neoplasms 
Interdigitating dendritic cell sarcoma 
Follicular dendritic cell sarcoma 
Other rare dendritic cell tumors 
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Appendix B 
List of Locales Recruited from via Craigslist 
Locale State 
New York City New York 
Houston Texas 
Cleveland Ohio 
San Francisco California 
Oahu Hawai`i 
Rochester Minnesota 
Ann Arbor Michigan  
Durham North Carolina 
Baltimore  Maryland 
Phoenix Arizona 
State College Pennsylvania 
Jacksonville Florida 
Indianapolis Indiana 
Philadelphia Pennsylvania 
Seattle Washington 
Denver Colorado  
Atlanta Georgia 
Boston Massachusetts  
Chicago Illinois 
Washington District of Columbia 
Los Angeles California 
Pittsburgh Pennsylvania 
Austin Texas 
Portland Oregon 
San Antonio Texas 
San Jose California 
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Appendix C 
Study Advertisement 
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Appendix D 
Demographic Questions - Survivors 
Age [drop-down menu] 
Gender (self-identify) _____________ 
Ethnicity (click all that apply) 
o Caucasian 
o African American 
o American Indian 
o Alaskan Native 
o Asian 
o Chinese 
o Korean 
o Japanese 
o Filipino 
o Vietnamese 
o Other Asian (please specify) ___________ 
o Native Hawaiian 
o Pacif 
o ic Islander 
o Other (please specify)_____________________________ 
In which country did you receive your cancer treatment? ________________ 
Diagnosis 
o Leukemia 
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o Lymphoma 
o Solid tumor (please describe) _____________ 
How severe do you consider your cancer? 
o Extremely severe 
o Very severe 
o Moderately severe 
o Slightly severe 
o Not severe 
o Not sure 
Have you been diagnosed with recurrence since your initial diagnosis? 
o Yes 
o No 
Have you been diagnosed with any other cancer since your initial diagnosis? 
o Yes  
o No 
Do you have healthcare insurance? 
o Yes 
o Medicare 
o Medicaid 
o Other (please specify) _______________ 
o No 
How much money do you estimate you have paid for treatment out-of-pocket? ___________ 
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How much money do you estimate you lost due to your cancer, not including treatment costs? 
___________ 
Are you currently employed? 
o Yes, full-time 
o Yes, part-time 
o No 
How many people live in your household? [drop-down menu] 
What is your annual household income? ___________ 
What is your marital status? 
o Married 
o Cohabitating 
o Single 
o Divorced 
o Widowed 
What treatments did you receive for your cancer? (click all that apply) 
o Chemotherapy 
o Radiation therapy 
o Bone marrow transplant 
o Watchful waiting 
o Other (please describe) 
When did your treatment end?  
o Date _____ 
o I am still receiving treatment 
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Appendix E 
Demographic Questions - Caregivers 
Age [drop-down menu] 
Gender (self-identify) _____________ 
Ethnicity (click all that apply) 
o Caucasian 
o African American 
o American Indian 
o Alaskan Native 
o Asian 
o Chinese 
o Korean 
o Japanese 
o Filipino 
o Vietnamese 
o Other Asian (please specify) ___________ 
o Native Hawaiian 
o Pacific Islander 
o Other (please specify)_____________________________ 
In which country did your loved one receive cancer treatment? _____________ 
Diagnosis received by your loved one: 
o Leukemia 
o Lymphoma 
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o Solid tumor (please describe) __________________ 
How severe do you consider your loved one’s cancer? 
o Extremely severe 
o Very severe 
o Moderately severe 
o Slightly severe 
o Not severe 
o Not sure 
Has your loved one been diagnosed with recurrence since your initial diagnosis? 
o Yes 
o No 
Has your loved one been diagnosed with any other cancer since your initial diagnosis? 
o Yes  
o No 
Does your loved one have healthcare insurance? 
o Yes 
o Medicare 
o Medicaid 
o Other (please specify) _______________ 
o No 
How much money do you estimate your family has paid for treatment out-of-pocket? 
___________ 
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How much money do you estimate your family lost due to your cancer, not including treatment 
costs? ___________ 
Are you currently employed? 
o Yes, full-time 
o Yes, part-time 
o No 
How many people live in your household? [drop-down menu] 
What is your annual household income? ___________ 
What is your marital status? 
o Married 
o Cohabitating 
o Single 
o Divorced 
o Widowed 
What treatments did your loved one receive for cancer? (click all that apply) 
o Chemotherapy 
o Radiation therapy 
o Bone marrow transplant 
o Watchful waiting 
o Other (please describe) 
When did your loved one’s treatment end?  
o Date _____ 
o She/he is still receiving treatment 
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Appendix F 
PTGI - Survivor 
Indicate for each of the statements below the degree to which this change occurred in your life as 
a result of cancer, using the following scale. 
 
0 = I did not experience this change as a result of my cancer. 
1 = I experienced this change to a very small degree as a result of my cancer. 
2 = I experienced this change to a small degree as a result of my cancer. 
3 = I experienced this change to a moderate degree as a result of my cancer. 
4 = I experienced this change to a great degree as a result of my cancer. 
5 = I experienced this change to a very great degree as a result of my cancer.  
 
Possible Areas of Growth and Change 
1. I changed my priorities about what is important in life.   0  1  2  3  4  5 
2. I have a greater appreciation for the value of my own life.  0  1  2  3  4  5 
3. I developed new interests.       0  1  2  3  4  5 
4. I have a greater feeling of self-reliance.    0  1  2  3  4  5 
5. I have a better understanding of spiritual matters.   0  1  2  3  4  5 
6. I more clearly see that I can count on people in times of trouble. 0  1  2  3  4  5 
7. I established a new path for my life.     0  1  2  3  4  5 
8. I have a greater sense of closeness with others.   0  1  2  3  4  5 
9. I am more willing to express my emotions.    0  1  2  3  4  5 
10. I know better that I can handle difficulties.    0  1  2  3  4  5 
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11. I am able to do better things with my life.    0  1  2  3  4  5 
12. I am better able to accept the way things work out.   0  1  2  3  4  5 
13. I can better appreciate each day.     0  1  2  3  4  5 
14. New opportunities are available which wouldn’t have been otherwise.  0  1  2  3  4  5 
15. I have more compassion for others.     0  1  2  3  4  5  
16. I put more effort into my relationships.    0  1  2  3  4  5 
17. I am more likely to change things which need changing.  0  1  2  3  4  5 
18. I have a stronger religious faith.     0  1  2  3  4  5 
19. I discovered that I’m stronger than I thought I was.   0  1  2  3  4  5 
20. I learned a great deal about how wonderful people are.  0  1  2  3  4  5 
21. I better accept needing others.     0  1  2  3  4  5 
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Appendix G 
PTGI - Caregivers 
Indicate for each of the statements below the degree to which this change occurred in your life as 
a result of cancer, using the following scale. 
 
0 = I did not experience this change as a result of my loved one’s cancer. 
1 = I experienced this change to a very small degree as a result of my loved one’s cancer. 
2 = I experienced this change to a small degree as a result of my loved one’s cancer. 
3 = I experienced this change to a moderate degree as a result of my loved one’s cancer. 
4 = I experienced this change to a great degree as a result of my loved one’s cancer. 
5 = I experienced this change to a very great degree as a result of my loved one’s cancer.  
 
Possible Areas of Growth and Change 
1. I changed my priorities about what is important in life.   0  1  2  3  4  5 
2. I have a greater appreciation for the value of my own life.  0  1  2  3  4  5 
3. I developed new interests.       0  1  2  3  4  5 
4. I have a greater feeling of self-reliance.    0  1  2  3  4  5 
5. I have a better understanding of spiritual matters.   0  1  2  3  4  5 
6. I more clearly see that I can count on people in times of trouble. 0  1  2  3  4  5 
7. I established a new path for my life.     0  1  2  3  4  5 
8. I have a greater sense of closeness with others.   0  1  2  3  4  5 
9. I am more willing to express my emotions.    0  1  2  3  4  5 
10. I know better that I can handle difficulties.    0  1  2  3  4  5 
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11. I am able to do better things with my life.    0  1  2  3  4  5 
12. I am better able to accept the way things work out.   0  1  2  3  4  5 
13. I can better appreciate each day.     0  1  2  3  4  5 
14. New opportunities are available which wouldn’t have been otherwise.  0  1  2  3  4 5 
15. I have more compassion for others.     0  1  2  3  4  5  
16. I put more effort into my relationships.    0  1  2  3  4  5 
17. I am more likely to change things which need changing.  0  1  2  3  4  5 
18. I have a stronger religious faith.     0  1  2  3  4  5 
19. I discovered that I’m stronger than I thought I was.   0  1  2  3  4  5 
20. I learned a great deal about how wonderful people are.  0  1  2  3  4  5 
21. I better accept needing others.     0  1  2  3  4  5 
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Appendix H 
IOCv2 - Survivors 
Indicate your agreement with each item on a 5-point scale: 
1 = Strongly Disagree 
2 = Disagree 
3 = Neutral 
4 = Agree 
5 = Strongly Agree 
1. I do not take my body for granted since the cancer. 
2. Having had cancer has made me more concerned about my health. 
3. I am more aware of physical problems or changes in my body since having had cancer. 
4. Having had cancer has made me take better care of myself (my health). 
5. I consider myself to be a cancer survivor. 
6. I feel a sense of pride or accomplishment from surviving cancer. 
7. I learned something about myself because of having had cancer. 
8. I feel that I am a role model to other people with cancer. 
9. Having had cancer makes me feel unsure about my future. 
10.  I feel like time in my life is running out. 
11. I worry about the cancer coming back or about getting another cancer. 
12. Having had cancer makes me feel uncertain about my health. 
13. I worry about my future. 
14. New symptoms (e.g. aches, pains, getting sick or the flu) make me worry about the 
cancer coming back. 
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15. I worry about my health. 
16. I am concerned that my energy has not returned to what it was before I had cancer. 
17. I am bothered that my body cannot do what it could before having had cancer. 
18. Having had cancer has made me feel old. 
19. I worry about how my body looks. 
20. I feel disfigured. 
21. I sometimes wear clothing to cover up parts of my body I don’t want others to see. 
22. I feel a special bond with people with cancer. 
23. Because I had cancer, I am more understanding of what other people may feel when they 
are seriously ill. 
24. Having had cancer has made me more willing to help others. 
25. I feel that I should give something back to others because I survived cancer. 
26. I feel guilty today for not having been available to my family when I had cancer. 
27. I feel like cancer runs my life. 
28. Having had cancer has made me feel like some people (friends, family, co-workers) do 
not understand me. 
29. Uncertainty about my future affects my decisions to make plans (examples: work, 
recreation/travel, get married, get involved in relationships, have a family, go to school). 
30. Having had cancer keeps me from doing activities I enjoy (examples: travel, socializing, 
recreation, time with family). 
31. On-going cancer-related or treatment-related symptoms (for example, bladder or bowel 
control, lymphedema, hair loss, scars, infertility, premature menopause, lack of energy, 
impotence//sexual problems, aches, pain, or physical discomfort) interfere with my life.  
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32. Having had cancer turned into a reason to make changes in my life. 
33. Because of cancer I have become better about expressing what I want. 
34. Because of cancer I have more confidence in myself. 
35. Having had cancer has given me direction in life. 
36. Because of having had cancer I feel that I have more control of my life. 
37. Uncertainties about my health or future have made me delay getting married or getting 
involved in a serious relationship. 
38. I wonder how to tell a potential spouse, partner, boyfriend or girlfriend that I have had 
cancer. 
39. I worry about not having a spouse, partner, boyfriend or girlfriend. 
40. I am open and willing to discuss my cancer with my spouse/partner. 
41. My spouse/partner is open and willing to discuss my cancer with me. 
42. Uncertainties about my health has caused problems in my relationship with my 
spouse/partner. 
43. I worry about my spouse/partner leaving me if I were to become ill again. 
44. I am concerned about not being able to work if I become ill again. 
45. Concerns about losing health insurance keep me in the job I have now. 
46. I worry about being forced to retire or quit work before I am ready. 
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Appendix I 
IOCv2 - Caregivers 
Indicate your agreement with each item on a 5-point scale: 
1 = Strongly Disagree 
2 = Disagree 
3 = Neutral 
4 = Agree 
5 = Strongly Agree 
1. I do not take my body for granted since the cancer. 
2. Having a loved one who had cancer has made me more concerned about my health. 
3. I am more aware of physical problems or changes in my body since my loved one’s 
cancer. 
4. My loved one’s cancer has made me take better care of myself (my health). 
5. I consider my loved one to be a cancer survivor. 
6. I feel a sense of pride or accomplishment from helping my loved one survive cancer. 
7. I learned something about myself because of my loved one’s cancer. 
8. I feel that I am a role model to other caregivers of people with cancer. 
9. My loved one’s cancer makes me feel unsure about my future. 
10.  I feel like time in my life is running out. 
11. I worry about the cancer coming back or about her/him getting another cancer. 
12. Our experience with cancer makes me feel uncertain about my health. 
13. I worry about my future. 
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14. New symptoms (e.g. aches, pains, getting sick or the flu) make me worry about the 
cancer coming back. 
15. I worry about my health. 
16. I am concerned that my energy has not returned to what it was before my loved one had 
cancer. 
17. I am bothered that my body cannot do what it could before my loved one had cancer. 
18. My loved one’s cancer has made me feel old. 
19. I feel a special bond with caregivers of people with cancer. 
20. Because of cancer, I am more understanding of what other people may feel when they are 
seriously ill. 
21. My loved one’s cancer has made me more willing to help others. 
22. I feel that I should give something back to others because my loved one survived cancer. 
23. I feel guilty today for not having been available to my family when my loved one had 
cancer. 
24. I feel like cancer runs my life. 
25. My loved one’s cancer has made me feel like some people (friends, family, co-workers) 
do not understand me. 
26. Uncertainty about my future affects my decisions to make plans (examples: work, 
recreation/travel, get married, get involved in relationships, have a family, go to school). 
27. My loved one’s cancer keeps me from doing activities I enjoy (examples: travel, 
socializing, recreation, time with family). 
28. My loved one’s on-going cancer-related or treatment-related symptoms (for example, 
bladder or bowel control, lymphedema, hair loss, scars, infertility, premature menopause, 
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lack of energy, impotence//sexual problems, aches, pain, or physical discomfort) interfere 
with my life.  
29. My loved one’s cancer turned into a reason to make changes in my life. 
30. Because of my loved one’s cancer I have become better about expressing what I want. 
31. Because of cancer I have more confidence in myself. 
32. My loved one’s cancer has given me direction in life. 
33. Because of my loved one’s cancer I feel that I have more control of my life. 
34. Uncertainties about my loved one’s health or future have made me delay getting married 
or getting involved in a serious relationship. 
35. I wonder how to tell a potential spouse, partner, boyfriend or girlfriend that my loved one 
had cancer. 
36. I worry about not having a spouse, partner, boyfriend or girlfriend. 
37. I am open and willing to discuss my loved one’s cancer with my spouse/partner. 
38. My spouse/partner is open and willing to discuss my loved one’s cancer with me. 
39. Uncertainties about my health has caused problems in my relationship with my 
spouse/partner. 
40. I worry about my spouse/partner leaving me if my loved one became ill again. 
41. I am concerned about not being able to work if my loved one became ill again. 
42. Concerns about losing health insurance keep me in the job I have now. 
43. I worry about being forced to retire or quit work before I am ready. 
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Appendix J 
Scoring Instructions for the IOCv2 
Reverse code items 40 and 41 by subtracting the score obtained from 6. 
Sum the item scores in each scale/subscale: 
Positive Impact Scale: 1, 2, 3, 4, 5, 6, 7, 8, 22, 23, 24, 25, 33, 34, 35, 36, 37 
Altruism and Empathy Subscale: 22, 23, 24, 25 
Health Awareness Subscale: 1, 2, 3, 4 
Meaning of Cancer Subscale: 33, 34, 35, 36, 37 
Positive Self-Evaluation Subscale: 5, 6, 7, 8 
Negative Impact Scale: 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 26, 27, 28, 29, 30, 31, 32 
Appearance Concerns Subscale: 19, 20, 21 
Body Change Concerns Subscale: 16, 17, 18 
Life Interferences Subscale: 26, 27, 28, 29, 30, 31, 32 
Worry Subscale: 9, 10, 11, 12, 13, 14, 15 
Employment Concerns: 44, 45, 46 
Relationship Concerns (Not Partnered): 37, 38, 39 
Relationship Concerns (Partnered): 40, 41, 42, 43 
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Appendix K  
CDC HRQoL – Survivors and Caregivers 
1. Would you say that in general your health is: 
a. Excellent    1 
b. Very good    2 
c. Good     3 
d. Fair     4 
e. Poor     5 
f. Don’t know/not sure   7 
g. Refused    9 
2. Now thinking about your physical health, which includes physical illness and injury, for 
how many days during the past 30 days was your physical health not good? 
a. Number of days ___ 
b. None  88 
c. Not sure 77 
d. Refused  99 
3. Now thinking about your mental health, which includes stress, depression, and problems 
with emotions, for how many days during the past 30 days was your mental health not 
good? 
a. Number of days ___ 
b. None  88 
c. Not sure 77 
d. Refused  99 
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4. During the past 30 days, for about how many days did poor physical or mental health 
keep you from doing your usual activities, such as self-care, work, or recreation? 
a. Number of days ___ 
b. None  88 
c. Not sure 77 
d. Refused  99 
 
Symptom Module 
1. During the past 30 days, for about how many days did PAIN make it hard for you to do 
your usual activities, such as self-care, work, or recreation? 
a. Number of days ___ 
b. None  88 
c. Not sure 77 
d. Refused  99 
2. During the past 30 days, for about how many days have you felt SAD, BLUE, or 
DEPRESSED?  
a. Number of Days ___ 
b. None  88 
c. Not sure 77 
d. Refused  99 
3. During the past 30 days, for about how many days have you felt WORRIED, TENSE, or 
ANXIOUS?  
a. Number of Days ___ 
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b. None  88 
c. Not sure 77 
d. Refused  99 
4. During the past 30 days, for about how many days have you felt you did NOT get 
ENOUGH REST or SLEEP? 
a. Number of Days ___ 
b. None  88 
c. Not sure 77 
d. Refused  99 
5. During the past 30 days, for about how many days have you felt VERY HEALTHY AND 
FULL OF ENERGY? 
a. Number of days ___ 
b. None  88 
c. Not sure 77 
d. Refused  99 
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Appendix L 
The OSS-3 and Scoring System – Survivors and Caregivers 
1. How easy can you get help from neighbors if you should need it? 
a. Very easy  5 points 
b. Easy  4 points 
c. Possible 3 points 
d. Difficult 2 points  
e. Very difficult 1 point 
2. How many people are so close to you that you can count on them if you have serious 
problems? 
a. None  1 point 
b. 1-2  2 points 
c. 3-5  3 points 
d. 6+  4 points 
3. How much concern do people show in what you are doing? 
a. A lot  5 points 
b. Some  4 points 
c. Uncertain 3 points 
d. Little  2 points 
e. None   1 point 
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